<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6826424</article-id><article-id pub-id-type="doi">10.3390/cancers11101482</article-id><article-id pub-id-type="publisher-id">cancers-11-01482</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>An Integrated Bioinformatics Analysis Repurposes an Antihelminthic Drug Niclosamide for Treating HMGA2-Overexpressing Human Colorectal Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Leung</surname><given-names>Stephen Wan</given-names></name><xref ref-type="aff" rid="af1-cancers-11-01482">1</xref></contrib><contrib contrib-type="author"><name><surname>Chou</surname><given-names>Chia-Jung</given-names></name><xref ref-type="aff" rid="af2-cancers-11-01482">2</xref><xref ref-type="aff" rid="af3-cancers-11-01482">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7873-132X</contrib-id><name><surname>Huang</surname><given-names>Tsui-Chin</given-names></name><xref ref-type="aff" rid="af2-cancers-11-01482">2</xref><xref ref-type="aff" rid="af3-cancers-11-01482">3</xref><xref ref-type="aff" rid="af4-cancers-11-01482">4</xref><xref ref-type="aff" rid="af5-cancers-11-01482">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4004-2518</contrib-id><name><surname>Yang</surname><given-names>Pei-Ming</given-names></name><xref ref-type="aff" rid="af2-cancers-11-01482">2</xref><xref ref-type="aff" rid="af3-cancers-11-01482">3</xref><xref ref-type="aff" rid="af4-cancers-11-01482">4</xref><xref ref-type="aff" rid="af5-cancers-11-01482">5</xref><xref rid="c1-cancers-11-01482" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-11-01482"><label>1</label>Department of Radiation Oncology, Yuan&#x02019;s General Hospital, Kaohsiung 80249, Taiwan; <email>lwan@ms36.hinet.net</email></aff><aff id="af2-cancers-11-01482"><label>2</label>Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; <email>coll78418@yahoo.com.tw</email> (C.-J.C.); <email>tsuichin@tmu.edu.tw</email> (T.-C.H.)</aff><aff id="af3-cancers-11-01482"><label>3</label>PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan</aff><aff id="af4-cancers-11-01482"><label>4</label>TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan</aff><aff id="af5-cancers-11-01482"><label>5</label>Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan</aff><author-notes><corresp id="c1-cancers-11-01482"><label>*</label>Correspondence: <email>yangpm@tmu.edu.tw</email>; Tel.: +886-2-2697-2035 (ext.143)</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>11</volume><issue>10</issue><elocation-id>1482</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Aberrant overexpression of high mobility group AT-hook 2 (HMGA2) is frequently found in cancers and HMGA2 has been considered an anticancer therapeutic target. In this study, a pan-cancer genomics survey based on Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) data indicated that HMGA2 was mainly overexpressed in gastrointestinal cancers including colorectal cancer. Intriguingly, HMGA2 overexpression had no prognostic impacts on cancer patients&#x02019; overall and disease-free survivals. In addition, HMGA2-overexpressing colorectal cancer cell lines did not display higher susceptibility to a previously identified HMGA2 inhibitor (netroposin). By microarray profiling of HMGA2-driven gene signature and subsequent Connectivity Map (CMap) database mining, we identified that S100 calcium-binding protein A4 (S100A4) may be a druggable vulnerability for HMGA2-overexpressing colorectal cancer. A repurposing S100A4 inhibitor, niclosamide, was found to reverse the HMGA2-driven gene signature both in colorectal cancer cell lines and patients&#x02019; tissues. In vitro and in vivo experiments validated that HMGA2-overexpressing colorectal cancer cells were more sensitive to niclosamide. However, inhibition of S100A4 by siRNAs and other inhibitors was not sufficient to exert effects like niclosamide. Further RNA sequencing analysis identified that niclosamide inhibited more cell-cycle-related gene expression in HMGA2-overexpressing colorectal cancer cells, which may explain its selective anticancer effect. Together, our study repurposes an anthelminthic drug niclosamide for treating HMGA2-overexpression colorectal cancer.</p></abstract><kwd-group><kwd>bioinformatics</kwd><kwd>Connectivity Map</kwd><kwd>colorectal cancer</kwd><kwd>drug repurposing</kwd><kwd>HMGA2</kwd><kwd>S100A4</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-11-01482"><title>1. Introduction</title><p>High mobility group adenine&#x02013;thymine (AT)-hook 2 (HMGA2) is a member of the non-histone chromosomal high mobility group (HMG) protein family and acts as an architectural factor. HMGA2 consists of three basic DNA-binding domains (AT-hooks) that bind nuclear DNA in the adenine&#x02013;thymine (AT)-rich regions. HMGA2 indirectly regulates gene transcription via changing the DNA structure and allowing the assembly of protein complexes to regulate transcription [<xref rid="B1-cancers-11-01482" ref-type="bibr">1</xref>]. HMGA2 is essential for embryonic morphogenesis and its expression is at an undetectable level in the majority of normal adult tissues [<xref rid="B2-cancers-11-01482" ref-type="bibr">2</xref>,<xref rid="B3-cancers-11-01482" ref-type="bibr">3</xref>]. HMGA2 is frequently overexpressed in cancers and is considered a potential therapeutic target for drug development [<xref rid="B4-cancers-11-01482" ref-type="bibr">4</xref>,<xref rid="B5-cancers-11-01482" ref-type="bibr">5</xref>,<xref rid="B6-cancers-11-01482" ref-type="bibr">6</xref>,<xref rid="B7-cancers-11-01482" ref-type="bibr">7</xref>,<xref rid="B8-cancers-11-01482" ref-type="bibr">8</xref>,<xref rid="B9-cancers-11-01482" ref-type="bibr">9</xref>,<xref rid="B10-cancers-11-01482" ref-type="bibr">10</xref>,<xref rid="B11-cancers-11-01482" ref-type="bibr">11</xref>,<xref rid="B12-cancers-11-01482" ref-type="bibr">12</xref>,<xref rid="B13-cancers-11-01482" ref-type="bibr">13</xref>]. However, no successful drugs have been developed to selectively kill HMGA2-overexpressing cancers.</p><p>Niclosamide is an anthelmintic drug used to treat tapeworm infestations through inhibiting glucose uptake, oxidative phosphorylation and anaerobic metabolism in the tapeworm [<xref rid="B14-cancers-11-01482" ref-type="bibr">14</xref>]. Accumulating evidences indicate that niclosamide is a multi-targeted drug exhibiting anticancer effects. The identified targets include Wnt/&#x003b2;-catenin, mammalian target of rapamycin complex 1 (mTORC1), signal transducer and activator of transcription 3 (STAT3), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#x003ba;B), and Notch signaling pathways [<xref rid="B15-cancers-11-01482" ref-type="bibr">15</xref>,<xref rid="B16-cancers-11-01482" ref-type="bibr">16</xref>]. Niclosamide has been shown to elicit anticancer activity against adenomatous polyposis coli (APC)-mutated colorectal cancer through downregulating the Wnt signaling pathway [<xref rid="B17-cancers-11-01482" ref-type="bibr">17</xref>]. In addition, niclosamide suppresses S100 calcium-binding protein A4 (S100A4)-mediated colorectal metastasis, which also acts via intervening in the Wnt signaling pathway [<xref rid="B18-cancers-11-01482" ref-type="bibr">18</xref>]. Recently, a phase II clinical trial has already demonstrated the safety and efficiency of niclosamide for treating metastatic colorectal cancers [<xref rid="B19-cancers-11-01482" ref-type="bibr">19</xref>].</p><p>In this study based on the integration of bioinformatics analyses and in vitro/in vivo experimental validation, we found that HMGA2 is not a suitable prognostic biomarker and therapeutic target in colorectal cancer. However, HMGA2 overexpression in colorectal cancer cells leads to an increased sensitivity to an anthelminthic drug niclosamide. Our study provides a novel therapeutic strategy for HMGA2-overexpressing colorectal cancer.</p></sec><sec sec-type="results" id="sec2-cancers-11-01482"><title>2. Results</title><sec id="sec2dot1-cancers-11-01482"><title>2.1. Pan-Cancer Analyses of HMGA2 Gene Expression</title><p>To gain a global insight into the role of HMGA2 in cancers, gene expression profiles of HMGA2 in various types of normal and cancerous cell lines and tissues were analyzed using the BioGPS (<uri xlink:href="http://biogps.org">http://biogps.org</uri>) [<xref rid="B20-cancers-11-01482" ref-type="bibr">20</xref>,<xref rid="B21-cancers-11-01482" ref-type="bibr">21</xref>,<xref rid="B22-cancers-11-01482" ref-type="bibr">22</xref>] and Gene Expression Profiling Interactive Analysis (GEPIA; <uri xlink:href="http://gepia">http://gepia</uri>. cancer-pku.cn) databases [<xref rid="B23-cancers-11-01482" ref-type="bibr">23</xref>,<xref rid="B24-cancers-11-01482" ref-type="bibr">24</xref>]. Two datasets, GeneAtlas U133A, gcrma [<xref rid="B25-cancers-11-01482" ref-type="bibr">25</xref>] and Cancer Cell Line Encyclopedia (CCLE) [<xref rid="B26-cancers-11-01482" ref-type="bibr">26</xref>] with the probe 208025_s_at and 638_at, respectively were used in BioGPS analysis. The dataset GeneAtlas U133A, gcrma provides a tissue-specific pattern of mRNA expression [<xref rid="B25-cancers-11-01482" ref-type="bibr">25</xref>]. As shown in <xref ref-type="fig" rid="cancers-11-01482-f001">Figure 1</xref>A, HMGA2 is highly expressed in bronchial epithelial cells, colorectal adenocarcinoma, and smooth muscle. Low HMGA2 expression is observed in other normal cells and tissues including colon. The Cancer Cell Line Encyclopedia (CCLE) dataset consists of the gene expression profiles from 917 human cancer cell line spanning 36 cancer types [<xref rid="B26-cancers-11-01482" ref-type="bibr">26</xref>]. High expression of HMGA2 mRNA is found in various types of cancers, especially those originating from the biliary tract, large intestine (colon), esophagus, pancreas, and salivary gland (<xref ref-type="fig" rid="cancers-11-01482-f001">Figure 1</xref>A, the embedded graph).</p><p>To confirm the above observation, we mined The Cancer Genome Atlas (TCGA) data using the GEPIA database to compare the HMGA2 gene expression in normal and cancerous tissues. As shown in <xref ref-type="fig" rid="cancers-11-01482-f001">Figure 1</xref>B, HMGA2 was overexpressed in colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS). Taken together with the results of BioGPS and TCGA analyses, HMGA2 was commonly overexpressed in gastrointestinal cancers such as esophagus, stomach, colon and rectum.</p></sec><sec id="sec2dot2-cancers-11-01482"><title>2.2. HMGA2 Is Not a Suitable Prognosis Marker and Therapeutic Target</title><p>To investigate whether HMGA2 could serve as a prognosis marker, Kaplan&#x02013;Meier survival analysis was performed. Because HMGA2 was commonly overexpressed in gastrointestinal cancers (<xref ref-type="fig" rid="cancers-11-01482-f001">Figure 1</xref>), we focused on esophagus, stomach, colon, and rectum cancers. Surprisingly, HMGA2 overexpression could not predict the overall and disease-free survivals of patients with esophagus (ESCA), stomach (STAD), and colorectal (COAD + READ) cancers (<xref ref-type="fig" rid="cancers-11-01482-f002">Figure 2</xref>). To investigate whether HMGA2 was a potential therapeutic target, we established a HMGA2-overexpressing DLD-1 colorectal cancer cell line. The overexpression of HMGA2 mRNA and protein was confirmed by real-time quantitative polymerase chain reaction (qPCR) and Western blotting (<xref ref-type="fig" rid="cancers-11-01482-f003">Figure 3</xref>A). The cell growth rates of HMGA2-overexpressing (DLD-1-HMGA2) and vector-overexpressing (DLD-1-Vector) cells were similar (<xref ref-type="fig" rid="cancers-11-01482-f003">Figure 3</xref>B). However, DLD-1-HMGA2 cells exhibited higher tumorigenicity in mice (<xref ref-type="fig" rid="cancers-11-01482-f003">Figure 3</xref>C), confirming the oncogenic effect of HMGA2.</p><p>HMGA2 is an AT-specific minor groove-binding protein, therefore some DNA minor groove-binding drugs, such as netropsin, are found to inhibit HMGA binding to DNA [<xref rid="B27-cancers-11-01482" ref-type="bibr">27</xref>,<xref rid="B28-cancers-11-01482" ref-type="bibr">28</xref>]. To investigate whether netropsin can selectively kill HMGA2-overexpressing cancer cells, both DLD-1-Vector and DLD-1-HMGA2 cells were treated with netropsin, and then cell viability was examined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. However, the potency of netropsin toward DLD-1-Vector and DLD-1-HMGA2 cells was similar (<xref ref-type="fig" rid="cancers-11-01482-f003">Figure 3</xref>D). To further confirm that the effect of netropsin on colorectal cancer cell viability was not affected by HMGA2 expression, HCT116 cells with higher endogenous HMGA2 protein expression were used (<xref ref-type="fig" rid="cancers-11-01482-f003">Figure 3</xref>E). Consistently, similar cytotoxicity was observed in netropsin-treated DLD-1 and HCT116 cells (<xref ref-type="fig" rid="cancers-11-01482-f003">Figure 3</xref>F). Therefore, our results argued that HMGA2 may not a suitable prognosis biomarker and therapeutic target for colorectal cancer.</p></sec><sec id="sec2dot3-cancers-11-01482"><title>2.3. S100A4 Is a Potential Surrogate Therapeutic Target for HMGA2-Overexpressing Colorectal Cancer</title><p>To identify druggable vulnerability of HGMA2-overexpressing colorectal cancer, microarray analysis was performed and found that 396 gene probes were upregulated and 1450 gene probes were downregulated in DLD-1-HMGA2 cells (<xref ref-type="app" rid="app1-cancers-11-01482">Table S1</xref>). The top 10 up- and down-regulated genes are listed in <xref rid="cancers-11-01482-t001" ref-type="table">Table 1</xref>. The hallmark pathways were analyzed using the Gene Set Enrichment Analysis (GSEA) software [<xref rid="B29-cancers-11-01482" ref-type="bibr">29</xref>,<xref rid="B30-cancers-11-01482" ref-type="bibr">30</xref>,<xref rid="B31-cancers-11-01482" ref-type="bibr">31</xref>]. As shown in <xref ref-type="fig" rid="cancers-11-01482-f004">Figure 4</xref>A and <xref rid="cancers-11-01482-t002" ref-type="table">Table 2</xref>, three hallmarks with false discovery rate (FDR) &#x0003c; 0.25 were enriched in DLD-1-HMGA2 cells. The enrichment of epithelial&#x02013;mesenchymal transition (EMT) and angiogenesis was coincident with the causal role of HMGA2 in tumor metastasis [<xref rid="B8-cancers-11-01482" ref-type="bibr">8</xref>,<xref rid="B13-cancers-11-01482" ref-type="bibr">13</xref>]. The Venn diagram showed the four overlapped genes (<italic>MYLK</italic>, <italic>BDNF</italic>, <italic>PCOLCE2</italic>, and <italic>S100A4</italic>) among the leading-edge genes of EMT and angiogenesis, and top 10 up- and down-regulated genes (<xref ref-type="fig" rid="cancers-11-01482-f004">Figure 4</xref>B and the gene descriptions were shown in <xref rid="cancers-11-01482-t003" ref-type="table">Table 3</xref>). Their gene expression profiles were compared by mining the BioGPS and GEPIA databases. As shown in <xref ref-type="app" rid="app1-cancers-11-01482">Figure S1</xref>, <italic>S100A4</italic>, but not <italic>MYLK</italic>, <italic>BDNF</italic>, and <italic>PCOLCE2</italic>, exhibited higher expression in colorectal adenocarcinoma, but lower expression in normal colon tissues. In addition, higher <italic>S100A4</italic> expression was observed in various cancer types compared to <italic>MYLK</italic>, <italic>BDNF</italic>, and <italic>PCOLCE2</italic> (<xref ref-type="app" rid="app1-cancers-11-01482">Figure S2</xref>). <italic>S100A4</italic> is a well-known metastasis-inducing gene in colorectal cancer and <italic>S100A4</italic> inhibition for therapeutic intervention is suggested [<xref rid="B32-cancers-11-01482" ref-type="bibr">32</xref>,<xref rid="B33-cancers-11-01482" ref-type="bibr">33</xref>]. Although <italic>S100A4</italic> is classified as a gene related to angiogenesis, but not EMT, in the cancer hallmark collection of Molecular Signatures Database (MSigDB) [<xref rid="B31-cancers-11-01482" ref-type="bibr">31</xref>], it is annotated in gene ontology EMT biological process (<xref rid="cancers-11-01482-t003" ref-type="table">Table 3</xref>), which can be supported by previous studies [<xref rid="B32-cancers-11-01482" ref-type="bibr">32</xref>,<xref rid="B34-cancers-11-01482" ref-type="bibr">34</xref>]. Therefore, we thought that <italic>S100A4</italic> might serve as a potential therapeutic target for HMGA2-overexpressing colorectal cancer.</p><p>To confirm the S100A4 mRNA was upregulated in HMGA2-overexpressing DLD-1 cells, qPCR was performed. There were about 1.5-fold increase of S100A4 mRNA in DLD-1-HMGA2 cells compare to DLD-1-Vector cells (<xref ref-type="fig" rid="cancers-11-01482-f004">Figure 4</xref>C, the left part). The corresponding induction of S100A4 protein was verified by Western blotting (<xref ref-type="fig" rid="cancers-11-01482-f004">Figure 4</xref>C, the embedded graph in the right part). In addition, higher extracellular level of S100A4 protein was observed in DLD-1-HMGA2 cells (<xref ref-type="fig" rid="cancers-11-01482-f004">Figure 4</xref>C, the right part). To investigate the prognostic impact of S100A4 on overall and disease-free survivals in colorectal cancer, Kaplan&#x02013;Meier survival analysis was performed. Although S100A4 expression could not predict the overall survival, colorectal cancer patients with high S100A4 expression displayed poor disease-free survival (<xref ref-type="fig" rid="cancers-11-01482-f004">Figure 4</xref>D). Therefore, these results indicated that S100A4 might serve as a suitable molecular target for treating HMGA2-overexpressing colorectal cancer.</p></sec><sec id="sec2dot4-cancers-11-01482"><title>2.4. Connectivity Map (CMap) Analysis Identified that S100A4 Inhibition Reverses the HMGA2-Driven Gene Signature</title><p>The Connectivity Map (CMap) is a web-based database consisting of gene expression signatures from human cancer cell lines treated with small molecules or transfected with gene-encoding complementary (c)DNAs or short hairpin (sh)RNAs. By comparing the queried and existing gene signatures, the connections among genetic knockdown/overexpression or small molecules sharing similar or opposite effects can be found [<xref rid="B35-cancers-11-01482" ref-type="bibr">35</xref>,<xref rid="B36-cancers-11-01482" ref-type="bibr">36</xref>]. It is believed that, if the queried gene signature for a specific disease can be reversed in small-molecule-treated or gene-knockdown/overexpressing cells, the corresponding small molecules or genes (either knockdown or overexpression) might have therapeutic or suppressive effect against this disease [<xref rid="B35-cancers-11-01482" ref-type="bibr">35</xref>,<xref rid="B36-cancers-11-01482" ref-type="bibr">36</xref>]. Therefore, we employed CMap analysis to investigate the genetic dependency of HMGA2-overexpressing colorectal cancer. The differentially expressed genes (DEGs) with absolute Log<sub>2</sub> fold change more than three (<xref ref-type="app" rid="app1-cancers-11-01482">Table S2</xref>) were queried by the next-generation CMap database, CLUE (<uri xlink:href="https://clue.io/">https://clue.io/</uri>) [<xref rid="B37-cancers-11-01482" ref-type="bibr">37</xref>]. As shown in <xref ref-type="fig" rid="cancers-11-01482-f005">Figure 5</xref>A, genes (knockdown or overexpression) with positive and negative scores have similar and opposite gene signatures to HMGA2 overexpression, respectively. Surprisingly, the gene signature of DLD-1-HMGA2 cells was not reversed by HMGA2-knockdown (summary score = 0.0); however, it was reversed by S100A4-knockdown (summary score = &#x02212;88.19). These results suggest that HMGA2-driven gene signature can be reversed by S100A4 knockdown, but not HMGA2 knockdown. To further confirm the result of CMap prediction, a microarray expression profile from A549 cells transfected with S100A4 shRNA (GSE121628 [<xref rid="B38-cancers-11-01482" ref-type="bibr">38</xref>]) was obtained from the Gene Expression Omnibus (GEO) database at the National Center for Biotechnology Information (NCBI) [<xref rid="B39-cancers-11-01482" ref-type="bibr">39</xref>]. The effect of S100A4 knockdown on HMGA2-driven gene signature was analyzed using the GSEA and the enrichment plot was shown in <xref ref-type="app" rid="app1-cancers-11-01482">Figure S3A</xref>. We found that HMGA2-upregulated gene signature was enriched (<italic>p</italic> = 0.085) in sh-control cells, whereas HMGA2-downregulated gene signature was enriched (<italic>p</italic> = 0.03) in sh-S100A4-transfected cells, suggesting that S100A4 knockdown indeed reversed the HMGA2-driven gene signature.</p><p>Currently, several S100A4 inhibitors have been discovered through repurposing of existing drugs (<xref rid="cancers-11-01482-t004" ref-type="table">Table 4</xref>). These drugs can either inhibit S100A4 expression by suppressing Wnt/&#x003b2;-catenin pathway such as niclosamide [<xref rid="B18-cancers-11-01482" ref-type="bibr">18</xref>], calcimycin [<xref rid="B40-cancers-11-01482" ref-type="bibr">40</xref>,<xref rid="B41-cancers-11-01482" ref-type="bibr">41</xref>], and sulindac [<xref rid="B42-cancers-11-01482" ref-type="bibr">42</xref>], or disrupting S100A4/ Myosin-IIA interaction such as phenothiazines [<xref rid="B43-cancers-11-01482" ref-type="bibr">43</xref>,<xref rid="B44-cancers-11-01482" ref-type="bibr">44</xref>], and NSC-95397 [<xref rid="B45-cancers-11-01482" ref-type="bibr">45</xref>]. To investigate whether these drugs can reverse the HMGA2-driven gene signature, CMap analysis was performed. As shown in <xref ref-type="fig" rid="cancers-11-01482-f005">Figure 5</xref>B, only niclosamide (summary score = &#x02212;87.35) showed the potency to reverse the HMGA2-driven gene signature. Specifically, the connectivity scores of niclosamide (&#x02212;92.86) and S100A4 knockdown (&#x02212;99.03) were similar in HT29 human colorectal cells (<xref ref-type="fig" rid="cancers-11-01482-f005">Figure 5</xref>B), further supporting the potency of niclosamide to inhibit S100A4 in colorectal cancer. In addition, we queried the CMap database with the S100A4-knockdown gene signature in A549 cells (GSE121628; the queried DEGs were shown in <xref ref-type="app" rid="app1-cancers-11-01482">Table S2</xref>). The summary connectivity scores of niclosamide and S100A4 knockdown were 77.95 and 96.74, respectively (<xref ref-type="app" rid="app1-cancers-11-01482">Figure S3B</xref>), suggesting that the queried S100A4-knockdown gene signature mimicked the signatures of niclosamide and S100A4 knockdown in the CMap database. Therefore, we speculated that S100A4 inhibition by niclosamide may exhibit therapeutic benefit for HMGA2-overexpressing colorectal cancer.</p></sec><sec id="sec2dot5-cancers-11-01482"><title>2.5. Connectivity Map (CMap) Analysis Identified that S100A4 Inhibition by Niclosamide is Clinically Relevant in Colorectal Cancer</title><p>To understand whether the reversion of the HMGA2-driven gene signature provides clinical benefits, the gene expression profile of a colorectal cancer patient cohort (GSE32323 [<xref rid="B46-cancers-11-01482" ref-type="bibr">46</xref>]) was obtained from the GEO database. Next, the co-expressed genes with HMGA2 were analyzed and ranked using the GSEA software. The most similar and dissimilar genes to HMGA2 were illustrated on a heat map (<xref ref-type="fig" rid="cancers-11-01482-f006">Figure 6</xref>, the upper part) and the full gene list was shown in <xref ref-type="app" rid="app1-cancers-11-01482">Table S3</xref>. As expected, HMGA2 was upregulated in tumor tissues compared to the adjacent tissues. These genes were queried by the CMap database to compare the connectivity scores of HMGA2-knockdown, S100A4-knockdown, and niclosamide. As shown in <xref ref-type="fig" rid="cancers-11-01482-f006">Figure 6</xref> (the lower part), the HMGA2-driven gene signature in colorectal cancer patients was reversed by S100A4-knockdown (summary score = &#x02212;96.55) and niclosamide (summary score = &#x02212;81.98), but not by HMGA2-knockdown (summary score = &#x02212;2.63). These results were similar to those observed in HMGA2-overexpressing DLD-1 cells (<xref ref-type="fig" rid="cancers-11-01482-f005">Figure 5</xref>). Therefore, inhibition of S100A4 by niclosamide may have clinical benefits.</p></sec><sec id="sec2dot6-cancers-11-01482"><title>2.6. HMGA2-Overexpressing Colorectal Cancer Cells Are More Susceptible to Niclosamide</title><p>To validate the inhibition of S100A4 by niclosamide, DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of niclosamide for 48 h, and then Western blot analysis were performed. As shown in <xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>A (the upper part), niclosamide dose-dependently inhibited S100A4 protein expression. In addition, time-dependent inhibition of S100A4 protein by 1 &#x003bc;M niclosamide was also observed (<xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>A, the lower part). These results were similar to the previous study that repurposes niclosamide as a S100A4 inhibitor [<xref rid="B18-cancers-11-01482" ref-type="bibr">18</xref>]. To investigate the sensitivity of DLD-1-Vector and DLD-1-HMGA2 cells to niclosamide, cells were treated with various doses of niclosamide for 72 h, and then an MTT assay was performed. As shown in <xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>B, DLD-1-HMGA2 cells were more sensitive to niclosamide compared to DLD-1-Vector cells. To further confirm the effect of niclosamide, HCT116 cells with higher HMGA2 and S100A4 was used (<xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>C). Consistently, niclosamide inhibited S100A4 expression in HCT116 cells (<xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>C), and exhibited higher cytotoxicity toward HCT116 cells compared to DLD-1 cells (<xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>D).</p><p>To demonstrate the in vivo anticancer activity of niclosamide against HMGA2-overexpressing colorectal cancer, DLD-1-Vector and DLD-1-HMGA2 cells were transplanted simultaneously into the left and right flanks of nude mice (<xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>E, the upper part). Transplanted DLD-1-HMGA2 cells grew faster than DLD-1-Vector cells when equal cell numbers were subcutaneously injected (<xref ref-type="fig" rid="cancers-11-01482-f003">Figure 3</xref>C), therefore we injected 1 &#x000d7; 10<sup>6</sup> DLD-1-Vector and 1 &#x000d7; 10<sup>5</sup> DLD-1-HMGA2 cells for this experiment. However, DLD-1-HMGA2 xenografts still exhibited higher tumorigenicity in mice (<xref ref-type="fig" rid="cancers-11-01482-f007">Figure 7</xref>E, the lower part). Treatment with niclosamide had a trend to inhibit the growth of DLD-1-Vector xenografts despite no statistical significance. In contrast, the growth of DLD-1-HMGA2 xenografts were significantly (<italic>p</italic> &#x0003c; 0.01) suppressed by niclosamide. Therefore, niclosamide indeed displayed selective in vitro and in vivo anticancer activity against HMGA2-overexpressing colorectal cancer.</p></sec><sec id="sec2dot7-cancers-11-01482"><title>2.7. Inhibition of S100A4 Is Not Sufficient to Selectively Kill HMGA2-Overexpressing Colorectal Cancer Cells</title><p>CMap drugs of 10 &#x003bc;M are usually used to treat cancer cells and generate gene expression signatures, therefore the inability of other S100A4-inhibitory drugs to reverse HMGA2-driven gene signature might be due to the higher doses required for S100A4 inhibition (<xref rid="cancers-11-01482-t004" ref-type="table">Table 4</xref>). To test this possibility, the effect of sulindac was investigated. One hundred &#x003bc;M of sulindac has been shown to reduce S100A4 expression [<xref rid="B42-cancers-11-01482" ref-type="bibr">42</xref>], we also found that sulindac inhibited S100A4 protein expression (<xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>A). Surprisingly, it induced higher cytotoxicity toward DLD-1-Vector but not DLD-1-HMGA2 cells (<xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>B). This observation implies that S100A4 inhibition cannot fully explain the effect of niclosamide. It has been proposed that niclosamide inhibits S100A4 expression by suppressing Wnt/&#x003b2;-catenin pathway [<xref rid="B18-cancers-11-01482" ref-type="bibr">18</xref>]. We further examined whether Wnt/&#x003b2;-catenin inhibitors could exhibit selective cytotoxicity against HMGA2-overexpressing colorectal cancer cells. As shown in <xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>C, a Wnt/&#x003b2;-catenin inhibitor, cardamonin, inhibited S100A4 expression, but induced HMGA2 expression. Similar to the effect of sulindac, DLD-1-HMGA2 cells were more resistant to cardamonin (<xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>D). These results indicate that niclosamide is a better therapeutic drug for HMGA2-overexpressing colorectal cancer than other Wnt/&#x003b2;-catenin pathway inhibitors. In addition, inhibition of S100A4 is not sufficient to account for the effect of niclosamide.</p><p>To further confirm that role of S100A4, both DLD-1-Vector and DLD-1-HMGA2 cells were transfected with S100A4 siRNA, the reduction of S100A4 protein was ascertained by Western blot analysis (<xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>E, the embedded figure). However, S100A4 knockdown did not exhibit higher cytotoxicity in DLD-1-HMGA2 cells as niclosamide did (<xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>E), confirming that S100A4 downregulation was not sufficient to selectively kill HMGA2-overexpressing colorectal cancer cells. In addition, S100A4 knockdown did not further enhance the anticancer activity of niclosamide (<xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>E). To ascertain this observation, a long-term colony formation assay was performed. Again, S100A4 knockdown did not have higher cytotoxicity against DLD-1-HMGA2 cells (<xref ref-type="fig" rid="cancers-11-01482-f008">Figure 8</xref>F).</p></sec><sec id="sec2dot8-cancers-11-01482"><title>2.8. RNA Sequencing Identifies that Niclosamide Inhibits Cell Cycle-Related Genes in HMGA2-Overexpressing Colorectal Cancer Cells</title><p>Diverse pharmacological activities of niclosamide have been continuously identified [<xref rid="B47-cancers-11-01482" ref-type="bibr">47</xref>]. To understand the differential effect of niclosamide in HMGA2-low and HMGA2-high expressing colorectal cancer cells, RNA sequencing for niclosamide-treated DLD-1-Vector and DLD-1-HMGA2 cells were performed. There were 521 upregulated and 454 downregulated genes in niclosamide-treated DLD-1-Vector cells (<xref ref-type="app" rid="app1-cancers-11-01482">Table S4</xref>). For niclosamide-treated DLD-1-HMGA2 cells, 846 and 816 genes were upregulated and downregulated, respectively (<xref ref-type="app" rid="app1-cancers-11-01482">Table S5</xref>). The DEGs with absolute Log<sub>2</sub> fold change more than two were further analyzed. The Venn diagram showed the overlapping and specific genes regulated by niclosamide in both cells (<xref ref-type="fig" rid="cancers-11-01482-f009">Figure 9</xref>A). These genes were analyzed for Kyoto Encyclopedia of Genes and Genomes (KEGG [<xref rid="B48-cancers-11-01482" ref-type="bibr">48</xref>,<xref rid="B49-cancers-11-01482" ref-type="bibr">49</xref>,<xref rid="B50-cancers-11-01482" ref-type="bibr">50</xref>]) pathway enrichment using the WebGestalt (<uri xlink:href="http://www.webgestalt.org">http://www.webgestalt.org</uri>) web tool [<xref rid="B51-cancers-11-01482" ref-type="bibr">51</xref>,<xref rid="B52-cancers-11-01482" ref-type="bibr">52</xref>,<xref rid="B53-cancers-11-01482" ref-type="bibr">53</xref>]. We found that only 257 genes specifically downregulated by niclosamide in DLD-1-HMGA2 cells obtained statistically significant enrichment. As shown in <xref ref-type="fig" rid="cancers-11-01482-f009">Figure 9</xref>B, the most significant pathways were related to cell cycle progression (DNA replication and cell cycle) and DNA repair (homologous recombination and Fanconi anemia pathway). As a representative, the cell cycle pathway (hsa04114) mapping to niclosamide-downregulated genes in both cells was compared. As shown in <xref ref-type="fig" rid="cancers-11-01482-f009">Figure 9</xref>C, niclosamide upregulated two cyclin-dependent kinase (CDK) inhibitors (p15/Ink4b and p21/Cip1) and downregulated many cell cycle-related genes in DLD-1-HMGA2 cells, suggesting that it interfered with cell cycle progression. However, niclosamide only induced p21 expression but did not inhibit cell cycle-related genes in DLD-1-Vector cells (<xref ref-type="app" rid="app1-cancers-11-01482">Figure S4</xref>). Therefore, we speculated that niclosamide tends to interfere with cell cycle progression and DNA repair pathways in HMGA2-overexpressing colorectal cancer, which may account for its higher cytotoxicity.</p></sec></sec><sec sec-type="discussion" id="sec3-cancers-11-01482"><title>3. Discussion</title><p>Our results suggested that HMGA2 expression did not predict patients&#x02019; prognosis (overall and disease-free survivals) based on TCGA datasets (esophagus, stomach, colon, and rectum cancers). However, it remains controversial because negative prognostic impacts of HMGA2 overexpression in the above cancer types have been reported previously [<xref rid="B54-cancers-11-01482" ref-type="bibr">54</xref>,<xref rid="B55-cancers-11-01482" ref-type="bibr">55</xref>,<xref rid="B56-cancers-11-01482" ref-type="bibr">56</xref>,<xref rid="B57-cancers-11-01482" ref-type="bibr">57</xref>,<xref rid="B58-cancers-11-01482" ref-type="bibr">58</xref>,<xref rid="B59-cancers-11-01482" ref-type="bibr">59</xref>]. We hypothesized that such discrepancy may be resulted from the source of cancer patients&#x02019; data, which can be supported by a recent meta-analysis based on literatures (15 cancer types) and TCGA datasets (33 cancer types) [<xref rid="B60-cancers-11-01482" ref-type="bibr">60</xref>]. They found that high HMGA2 expression is associated with shorter overall and disease-free survivals in cancer patients. However, consistent results are only observed in six cancer types. For clear cell renal cell carcinoma, head and neck cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, patients with high HMGA2 expression have shorter overall survivals. For esophageal adenocarcinoma and ovarian carcinoma, no significant correlation was found [<xref rid="B60-cancers-11-01482" ref-type="bibr">60</xref>].</p><p>The aim of this study was to identify therapeutic agents selectively targeting HMGA2-overexpressing colorectal cancer. HMGA2 has been considered a therapeutic target in colorectal cancer. For example, HMGA2 silencing by small interfering (si)RNA, shRNA and micro(mi)RNA (such as miR-204 and miR-4500) was shown to inhibit cell growth and induce apoptosis in human colorectal cancer cells [<xref rid="B61-cancers-11-01482" ref-type="bibr">61</xref>,<xref rid="B62-cancers-11-01482" ref-type="bibr">62</xref>,<xref rid="B63-cancers-11-01482" ref-type="bibr">63</xref>,<xref rid="B64-cancers-11-01482" ref-type="bibr">64</xref>]. However, such observations imply that HMGA2 inhibition-based therapy will be obstructed in HMGA2-overexpressing cancers. Indeed, re-expression of HMGA2 reverses the inhibitory effect of miR-204 and miR-4500 [<xref rid="B63-cancers-11-01482" ref-type="bibr">63</xref>,<xref rid="B64-cancers-11-01482" ref-type="bibr">64</xref>]. Our recent study has shown that heat shock protein 90 (HSP90) interacts and stabilizes HMGA2 protein expression. A HSP90 inhibitor NVP-AUY922 is able to reduce HMGA2 expression and suppress HMGA-mediated EMT in colorectal cancer cells. Thus, NVP-AUY922 can be viewed as an HMGA2 inhibitor. However, knockdown of HMGA2 by siRNA increases the sensitivity of colorectal cancer cells to NVP-AUY922, whereas HMGA2 overexpression attenuates the anticancer effect of NVP-AUY922 [<xref rid="B65-cancers-11-01482" ref-type="bibr">65</xref>]. This study further supported the idea that the anticancer activity of HMGA2 inhibitors is limited by the endogenous expression of HMGA2 in colorectal cancer cells.</p><p>Drug repurposing is a promising strategy for the development of novel treatment modalities to fight against cancers. There are increasing repurposed drugs for colorectal cancer, including niclosamide [<xref rid="B66-cancers-11-01482" ref-type="bibr">66</xref>]. Currently, few clinical trials of niclosamide for treating colorectal and prostate cancers are ongoing (ClinicalTrials.gov; <uri xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</uri>). Most of them are still at the recruiting stage. The only one completed clinical trial is a phase I dose-escalation study testing oral niclosamide plus standard-dose enzalutamide (a nonsteroidal antiandrogen) in metastatic castration-resistant prostate cancer [<xref rid="B67-cancers-11-01482" ref-type="bibr">67</xref>]. However, the result is disappointing. The plasma concentration of niclosamide does not pass the threshold shown to inhibit prostate cancer growth [<xref rid="B67-cancers-11-01482" ref-type="bibr">67</xref>]. The finding that niclosamide inhibits S100A4-driven metastasis triggers a phase II clinical trial (ClinicalTrial.gov registration number: NCT02519582) to evaluate its safety and efficacy in metastatic colorectal cancer [<xref rid="B18-cancers-11-01482" ref-type="bibr">18</xref>,<xref rid="B19-cancers-11-01482" ref-type="bibr">19</xref>]. This trial is expected to be completed by August 2020 and hopes to demonstrate the feasibility of oral niclosamide for treating metastatic colorectal cancer.</p><p>It has been reported that niclosamide-mediated S100A4 downregulation contributes only its inhibitory effect on cell migration and invasion, but not on cell proliferation and colony formation in HCT116 cells [<xref rid="B18-cancers-11-01482" ref-type="bibr">18</xref>]. Similarly, we found that S100A4 silencing by siRNA did not enhance the inhibitory effect of niclosamide on cell viability. In addition, S100A4 inhibition by Wnt/&#x003b2;-catenin inhibitors (sulindac and cardamonin) did not exhibit higher cytotoxicity against HMGA2-overexpression DLD-1 cells. Therefore, we speculated that other mechanisms, in addition to Wnt/&#x003b2;-catenin and S100A4 inhibition, may involve in the selective anticancer effect of niclosamide against HMGA2-overexpressing colorectal cancer cells.</p><p>One limitation of this study is few biological replicates for microarray (two biological replicates) and RNA sequencing (two technical replicates from a single biological sample). A minimum of five biological replicates in microarray experiments is suggested to satisfy statistical power for the DEG analysis [<xref rid="B68-cancers-11-01482" ref-type="bibr">68</xref>]. However, the most acceptable numbers for biologists are usually three. In addition, two biological replicates are considered to be acceptable for network construction only [<xref rid="B69-cancers-11-01482" ref-type="bibr">69</xref>]. For RNA sequencing, at least six biological replicates are suggested [<xref rid="B70-cancers-11-01482" ref-type="bibr">70</xref>]. However, a large number of published RNA sequencing studies are performed based on few biological replicates (n &#x02264; 2), which may not estimate the level of biological variability in gene expression [<xref rid="B71-cancers-11-01482" ref-type="bibr">71</xref>].</p></sec><sec id="sec4-cancers-11-01482"><title>4. Materials and Methods </title><sec id="sec4dot1-cancers-11-01482"><title>4.1. Bioinformatics Analysis of Public Data</title><p>Gene expression profiles of <italic>HMGA2</italic>, <italic>MYLK</italic>, <italic>BDNF</italic>, <italic>PCOLCE2</italic>, and <italic>S100A4</italic> in various normal and cancerous cell lines and tissues were analyzed using the BioGPS and the Gene Expression Profiling Interactive Analysis (GEPIA) databases [<xref rid="B20-cancers-11-01482" ref-type="bibr">20</xref>,<xref rid="B21-cancers-11-01482" ref-type="bibr">21</xref>,<xref rid="B22-cancers-11-01482" ref-type="bibr">22</xref>,<xref rid="B24-cancers-11-01482" ref-type="bibr">24</xref>]. For BioGPS analysis, the following datasets (and gene probes) were selected: GeneAtlas U133A, gcrma (208025_s_at for <italic>HMGA2</italic>, 202555_s_at for <italic>MYLK</italic>, 206382_s_at for <italic>BDNF</italic>, 219295_s_at for <italic>PCOLCE2</italic>, and 203186_s_at for <italic>S100A4</italic>) and expression data from The Cancer Cell Line Encyclopedia (CCLE) (638_at for HMGA2) [<xref rid="B25-cancers-11-01482" ref-type="bibr">25</xref>,<xref rid="B26-cancers-11-01482" ref-type="bibr">26</xref>]. The prognostic impact of <italic>HMGA2</italic> and <italic>S100A4</italic> in cancers was analyzed using the GEPIA database. Kaplan&#x02013;Meier survival plots were generated using the GEPIA (<uri xlink:href="http://gepia.cancer-pku.cn/">http://gepia.cancer-pku.cn/</uri>) database [<xref rid="B23-cancers-11-01482" ref-type="bibr">23</xref>,<xref rid="B24-cancers-11-01482" ref-type="bibr">24</xref>], which is based on the expression data from The Cancer Genome Atlas (TCGA).</p></sec><sec id="sec4dot2-cancers-11-01482"><title>4.2. Microarray</title><p>Total RNA was isolated from untreated DLD-1-Vector and DLD-1-HMGA2 cells by the GENEzol TriRNA Pure Kit (Geneaid, New Taipei City, Taiwan). The mRNA profiles were analyzed using the Human OneArray Plus microarray by Phalanx Biotech (Hsinchu, Taiwan) with two biological replicates. The microarray raw data were deposited in NCBI GEO database (GSE136544). A moderated <italic>t</italic>-test using the limma package in R was performed to detect the differentially expressed genes (DEGs) [<xref rid="B72-cancers-11-01482" ref-type="bibr">72</xref>]. The <italic>p</italic> value was adjusted for multiple testing based on the false discovery rate (FDR) according to the Benjamini-Hochberg method [<xref rid="B73-cancers-11-01482" ref-type="bibr">73</xref>]. <xref ref-type="app" rid="app1-cancers-11-01482">Table S1</xref> listed the DEGs with |Log<sub>2</sub> fold-change| &#x0003e; 1, <italic>p</italic> value &#x0003c; 0.01, and adjust <italic>p</italic> value &#x0003c; 0.05. For the visualization of overlap genes, Venn diagrams were generated using the VENNY 2.1 web tool (<uri xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</uri>).</p></sec><sec id="sec4dot3-cancers-11-01482"><title>4.3. Gene Set Enrichment Analysis (GSEA) and Connectivity Map (CMap)</title><p>GSEA v2.2.2 software (Broad institute, Cambridge, MA, USA) [<xref rid="B29-cancers-11-01482" ref-type="bibr">29</xref>,<xref rid="B30-cancers-11-01482" ref-type="bibr">30</xref>] was used to analyze microarray data obtained from this study (GSE136544) and public resources (GSE32323 and GSE121628). The hallmark gene sets were selected for analysis [<xref rid="B31-cancers-11-01482" ref-type="bibr">31</xref>]. Genes were ranked by running a gene set type permutation test with Log<sub>2</sub> ratio ranking statistic for GSE136544 and GSE121628. For GSE32323, the most similar and dissimilar genes with HMGA2 were obtained by running a phenotype permutation test with signal-to-noise ranking statistic. Default settings were used for all other GSEA parameters. For the next-generation CMap analysis, the gene lists in <xref ref-type="app" rid="app1-cancers-11-01482">Tables S2 and S3</xref> were inputted to query the CLUE database (Last accessed on September 27, 2019) [<xref rid="B37-cancers-11-01482" ref-type="bibr">37</xref>]. Connections of HMGA2-driven gene signature to small molecules or gene knockdown/overexpression were obtained from the results and were viewed as a heat map.</p></sec><sec id="sec4dot4-cancers-11-01482"><title>4.4. RNA Sequencing and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Analysis</title><p>Total RNA was isolated from niclosamide (1 &#x003bc;M for 24 h)-treated and untreated DLD-1-Vector and DLD-1-HMGA2 cells by the GENEzol TriRNA Pure Kit (Geneaid, New Taipei City, Taiwan). The RNA samples were sequenced using the Illumina NovaSeq 6000 platform (San Diego, CA, USA) to generate 150 bp paired-end reads. Sequencing and data analysis were conducted by Novogene Bioinformatics Technology (Beijing, China) with two technical replicates from a single biological sample. The DEG analysis was performed using the DEGseq software [<xref rid="B74-cancers-11-01482" ref-type="bibr">74</xref>]. Reads were normalized with trimmed mean of M-values (TMM) method and <italic>p</italic> values were estimated by the Poisson distribution model. The DEGs were prepared according to the criteria: |Log<sub>2</sub> fold-change| &#x0003e; 1 and <italic>p</italic> value &#x0003c; 0.005. The full DEG list was shown in <xref ref-type="app" rid="app1-cancers-11-01482">Tables S4,S5</xref>. For the visualization of overlap genes, Venn diagrams were generated using the VENNY 2.1 web tool (<uri xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</uri>). The KEGG pathway enrichment was performed using the WebGestalt web tool (Last accessed on August 28, 2019) [<xref rid="B51-cancers-11-01482" ref-type="bibr">51</xref>,<xref rid="B52-cancers-11-01482" ref-type="bibr">52</xref>,<xref rid="B53-cancers-11-01482" ref-type="bibr">53</xref>]. Pathway mapping to cell cycle (hsa04114) was performed using the Advanced Pathway Painter v2.3.1 software (GSA GmbH, Rostock, Germany).</p></sec><sec id="sec4dot5-cancers-11-01482"><title>4.5. Materials</title><p>Roswell Park Memorial Institute (RPMI)-1640 medium, sodium pyruvate, L-glutamine, and antibiotic&#x02013;antimycotic solution were purchased from Life Technologies (Carlsbad, CA, USA). Fetal bovine serum (FBS) was purchased from GIBCO (Paisley, Scotland, UK). S100A4 antibody was purchased from DAKO (Glostrup, Denmark). HMGA2, GAPDH, and &#x003b2;-Actin antibodies were purchased from GeneTex (Hsinchu, Taiwan). Horseradish peroxidase-labeled goat anti-rabbit and anti-mouse, and donkey anti-goat secondary antibodies were purchased from Jackson ImmunoResearch (West Grove, PA, USA). Turbo green fluorescent protein (tGFP) antibody, pCMV6-HMGA2 and pCMV6-AC-GFP plasmids were purchased from OriGene (Rockville, MD, USA). S100A4 siRNA was purchased from Santa Cruz (Island, CA, USA). PolyJet&#x02122; In Vitro DNA Transfection Reagent was purchased from SignaGen Laboratories (Gaithersburg, MD, USA). Lipofectamine RNAiMAX Reagent was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Geneticin (G418) was purchased from Invivogen (San Diego, CA, USA). GENEzol TriRNA Pure Kit was purchased from Geneaid Biotech (New Taipei City, Taiwan). iScript cDNA Synthesis Kit was purchased from Bio-Rad Laboratories (Richmond, CA, USA). Netropsin, niclosamide, sulindac, dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), and crystal violet were purchased from Sigma Chemical (St. Louis, MO, USA). Cardamonin was purchased from Millipore (Bedford, MA, USA). Hybond-C Extra nitrocellulose membrane was purchased from GE Healthcare (Waukesha, WI, USA). The enhanced chemiluminescence (ECL) system was purchased from Perkin-Elmer (Seraing, Belgium). Protease and phosphatase inhibitor cocktails, X-ray film, and 2&#x000d7; SYBR Green PCR Master Mix were purchased from Roche (Indianapolis, IN, USA).</p></sec><sec id="sec4dot6-cancers-11-01482"><title>4.6. Cell Culture and Transfection</title><p>DLD-1 and HCT116 human colorectal cancer cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 1 mM sodium pyruvate, 1% L-glutamine, 1% antibiotic-antimycotic solution, and incubated at 37 &#x000b0;C in a humidified incubator containing 5% CO<sub>2</sub>. Stable HMGA2-overexpressing DLD-1 (DLD-1-HMGA2) and the corresponding vector-overexpressing (DLD-1-Vector) cell lines were established by transfecting tGFP-tagged pCMV6-HMGA2 and pCMV6-AC-GFP plasmids, respectively, and then stable clones were selected with 1 mg/mL G418. For siRNA knockdown analysis, cells were transfected with Lipofectamine RNAiMAX Reagent according to the manufacturer&#x02019;s instruction.</p></sec><sec id="sec4dot7-cancers-11-01482"><title>4.7. Determination of Cell Proliferation and Cell Viability</title><p>For the determination of cell proliferation, cells (1 &#x000d7; 10<sup>5</sup>) were plated in 60 mm dishes and cultured for 1&#x02013;4 days. Cells were harvested and cell number was counted by a hematocytometer. Cell viability was examined by an MTT assay. Cells were spread on 96-well plates and exposed to drugs. After 72 h, 0.5 mg/mL of MTT was added to each well and cells were incubated for 4 h. The blue MTT formazan precipitates were dissolved in 200 &#x003bc;L of DMSO. The absorbance at 550 nm was measured on a multi-well plate reader. For long-term colony formation assay, 500 cells were spread in a 24-well plate and 2&#x000d7; serially diluted with regular medium. After 10&#x02013;14 days, cells were fixed and stained with 0.5% crystal violet solution in 20% methanol.</p></sec><sec id="sec4dot8-cancers-11-01482"><title>4.8. Real-Time Quantitative Polymerase Chain Reaction (qPCR)</title><p>Total RNA was isolated by GENEzol TriRNA Pure Kit. The first-strand cDNA was synthesized using the iScript cDNA Synthesis Kit and then PCR was performed using the 2&#x000d7; SYBR Green PCR Master Mix and 200 nM of forward and reverse primers (human HMGA2: forward 5&#x02032;-AGTCCCTCTAAAGCAGCTCAAAAG-3&#x02032; and reverse 5&#x02032;-GCCATTTCCTAGGTCTGCCTC-3&#x02032;; human S100A4: forward 5&#x02032;-CTCAGCGCTTCTTCTTTC-3&#x02032; and reverse 5&#x02032;-GGGTCAGCAGCTCCTTT A-3&#x02032;; human &#x003b2;-Actin: forward 5&#x02032;-GTTGCTATCCAGGCTGTGCT-3&#x02032; and reverse 5&#x02032;-AGGGCATACCC CTCGTAGAT-3&#x02032;). Each assay was performed on a LightCycler Nano Real-Time PCR System (Roche) in triplicate, and the fold-changes in expression were derived using the comparative cycle threshold (CT) method calculated by LightCycler Nano Software v1.1 (Roche, Indianapolis, IN, USA).</p></sec><sec id="sec4dot9-cancers-11-01482"><title>4.9. Western Blot Analysis and Enzyme-Linked Immunosorbent Assay (ELISA)</title><p>Cells were lysed in an ice-cold buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM MgCl<sub>2</sub>, 2 mM EDTA, 1% NP-40, 10% glycerol, 1 mM DTT, 1&#x000d7; protease inhibitor cocktail and 1&#x000d7; phosphatase inhibitor cocktail) at 4 &#x000b0;C for 30 min. Cell lysates were separated on a sodium dodecyl sulfate (SDS)-polyacrylamide gel and then transferred onto the nitrocellulose membrane. The membrane was pre-hybridized in 5% skim milk/TBST (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20) and for 1 h, and then transferred to 1% bovine serum albumin (BSA)/TBST containing a primary antibody and incubated overnight at 4 &#x000b0;C. After washing with the TBST buffer, the membrane was submerged in 1% BSA/TBST containing a horseradish peroxidase-conjugated secondary antibody for 1 h. The membrane was washed with TBST buffer, and then developed with an ECL system and exposed to X-ray film. The uncropped images for Western blot figures were shown in <xref ref-type="app" rid="app1-cancers-11-01482">Figure S5</xref>. The densitometry readings/intensity ratio of each band were shown in <xref ref-type="app" rid="app1-cancers-11-01482">Figures S6, S7</xref>. To determine the protein level of extracellular S100A4, conditioned media from DLD-1-Vector and DLD-1-HMGA2 cells cultured for 24 h were collected and measured with ELISA commercial kits (Cloud-Clone Corp, Houston, TX, USA) according to the manufacturer&#x02019;s protocol.</p></sec><sec id="sec4dot10-cancers-11-01482"><title>4.10. Mice Tumor Xenograft Model</title><p>DLD-1-Vector and DLD-1-HMGA2 cells were subcutaneously injected into the left and right flanks of six-week-old female nude mice (BioLASCO, Taipei, Taiwan). Mice were treated with vehicle control (5% DMSO in PBS; <italic>n</italic> = 5) or intraperitoneal niclosamide injection (20 mg/kg/day, 5 days/week; <italic>n</italic> = 5) for four consecutive weeks. Tumor length and width were measured twice per week and volume was calculated by the formula: 0.5 &#x000d7; length &#x000d7; width<sup>2</sup>. All animal studies were approved by the Institutional Animal Care and Use Committee at the Taipei Medical University, Taiwan (LAC-2017-0279, 16 Nov 2017).</p></sec></sec><sec sec-type="conclusions" id="sec5-cancers-11-01482"><title>5. Conclusions</title><p>In summary, our study indicated that HMGA2 is not a suitable therapeutic target although it is overexpressed in cancers. Bioinformatics analyses indicated that HMGA2-overexpressing colorectal cancers shift their dependency from HMGA2 to S100A4 that predicts a poor disease-free survival in colorectal cancer patients. In addition, niclosamide (a S100A4 inhibitor) exhibits more effective cell killing in HMGA2-overexpressing DLD-1 cells, which may provide clinical benefits. Interestingly, inhibition of S100A4 cannot fully explain the sensitizing effect of niclosamide on HMGA2-overexpressing colorectal cancer cells, suggesting that additional mechanisms are involved. The results of RNA sequencing provide an alternative explanation for the selective anticancer activity by downregulating cell cycle-related genes in HMGA2-overexpressing cells. Nevertheless, our study provides a basis for treating HMGA2-overexpressing colorectal cancer by niclosamide, and the exact mechanism of action warrants further investigation.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the financial supported by the &#x0201c;WanFang Hospital, Chi-Mei Medical Center, and Hualien Tzu-Chi Hospital Joint Cancer Center Grant&#x02014;Focus on Colon Cancer Research&#x0201d; from the health and welfare surcharge of tobacco products of Taiwan, and the &#x0201c;TMU Research Center of Cancer Translational Medicine&#x0201d; from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.</p></ack><app-group><app id="app1-cancers-11-01482"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2072-6694/11/10/1482/s1">https://www.mdpi.com/2072-6694/11/10/1482/s1</uri>, Figure S1: Gene expression profiles of <italic>MYLK</italic>, <italic>BDNK</italic>, <italic>PCOLCE2</italic>, and <italic>S100A4</italic> in cell lines, Figure S2: Relative gene expression levels of <italic>HMGA2</italic>, <italic>MYLK</italic>, <italic>BDNK</italic>, <italic>PCOLCE2</italic>, and <italic>S100A4</italic> in normal and cancer tissues, Figure S3: Connectivity mapping for the gene signature in <italic>S100A4</italic>-knockdown A549 cells, Figure S4: The mapping of cell cycle pathway for the upregulated and downregulated genes in niclosamide-treated DLD-1-Vector cells, Figure S5: The whole uncropped images of the original Western blots, Figure S6: The band intensity and ratio for the Western blots in figures, Figure S7: The band intensity and ratio for the Western blots in Supplementary Figures, Table S1: Differentially expressed genes in DLD-1-HMGA2 vs. DLD-1-Vector cells, Table S2: The genes for Connectivity Map (CMap) analysis, Table S3: The HMGA2-correlated genes in colorectal cancer patients, Table S4: RNA sequencing for niclosamide-treated DLD-1-Vector cells, Table S5: RNA sequencing for niclosamide-treated DLD-1-HMGA2 cells.</p><supplementary-material content-type="local-data" id="cancers-11-01482-s001"><media xlink:href="cancers-11-01482-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>S.-W.L. and P.-M.Y. conceived and designed experiments, as well as coordinated and drafted the manuscript. C.-J.C. performed experiments. T.-C.H. performed microarray statistical analysis. P.-M.Y. performed the bioinformatics analyses.</p></notes><notes><title>Funding</title><p>This research was funded by Yuan&#x02019;s General Hospital, grant number 107YGH-TMU-05; Health and welfare surcharge of tobacco products, grant number MOHW108-TDU-B-212-124020; and Ministry of Education, grant number DP2-108-21121-01-C-03-05.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-11-01482"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozturk</surname><given-names>N.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Mehta</surname><given-names>A.</given-names></name><name><surname>Braun</surname><given-names>T.</given-names></name><name><surname>Barreto</surname><given-names>G.</given-names></name></person-group><article-title>HMGA proteins as modulators of chromatin structure during transcriptional activation</article-title><source>Front Cell Dev. Biol.</source><year>2014</year><volume>2</volume><fpage>e5</fpage><pub-id pub-id-type="doi">10.3389/fcell.2014.00005</pub-id><?supplied-pmid 25364713?><pub-id pub-id-type="pmid">25364713</pub-id></element-citation></ref><ref id="B2-cancers-11-01482"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfannkuche</surname><given-names>K.</given-names></name><name><surname>Summer</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>O.</given-names></name><name><surname>Hescheler</surname><given-names>J.</given-names></name><name><surname>Droge</surname><given-names>P.</given-names></name></person-group><article-title>The high mobility group protein HMGA2: A co-regulator of chromatin structure and pluripotency in stem cells?</article-title><source>Stem Cell Rev.</source><year>2009</year><volume>5</volume><fpage>224</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1007/s12015-009-9078-9</pub-id><?supplied-pmid 19551524?><pub-id pub-id-type="pmid">19551524</pub-id></element-citation></ref><ref id="B3-cancers-11-01482"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedele</surname><given-names>M.</given-names></name><name><surname>Battista</surname><given-names>S.</given-names></name><name><surname>Kenyon</surname><given-names>L.</given-names></name><name><surname>Baldassarre</surname><given-names>G.</given-names></name><name><surname>Fidanza</surname><given-names>V.</given-names></name><name><surname>Klein-Szanto</surname><given-names>A.J.</given-names></name><name><surname>Parlow</surname><given-names>A.F.</given-names></name><name><surname>Visone</surname><given-names>R.</given-names></name><name><surname>Pierantoni</surname><given-names>G.M.</given-names></name><name><surname>Outwater</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>3190</fpage><lpage>3198</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205428</pub-id><?supplied-pmid 12082634?><pub-id pub-id-type="pmid">12082634</pub-id></element-citation></ref><ref id="B4-cancers-11-01482"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedele</surname><given-names>M.</given-names></name><name><surname>Fusco</surname><given-names>A.</given-names></name></person-group><article-title>HMGA and cancer</article-title><source>BBA-Gene Regul. Mech.</source><year>2010</year><volume>1799</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2009.11.007</pub-id><?supplied-pmid 20123067?><pub-id pub-id-type="pmid">20123067</pub-id></element-citation></ref><ref id="B5-cancers-11-01482"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Meng</surname><given-names>Q.</given-names></name></person-group><article-title>Downregulation of HMGA2 inhibits cellular proliferation and invasion, improves cellular apoptosis in prostate cancer</article-title><source>Tumour Biol.</source><year>2016</year><volume>37</volume><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3853-9</pub-id><?supplied-pmid 26242267?><pub-id pub-id-type="pmid">26242267</pub-id></element-citation></ref><ref id="B6-cancers-11-01482"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Cello</surname><given-names>F.</given-names></name><name><surname>Hillion</surname><given-names>J.</given-names></name><name><surname>Hristov</surname><given-names>A.</given-names></name><name><surname>Wood</surname><given-names>L.J.</given-names></name><name><surname>Mukherjee</surname><given-names>M.</given-names></name><name><surname>Schuldenfrei</surname><given-names>A.</given-names></name><name><surname>Kowalski</surname><given-names>J.</given-names></name><name><surname>Bhattacharya</surname><given-names>R.</given-names></name><name><surname>Ashfaq</surname><given-names>R.</given-names></name><name><surname>Resar</surname><given-names>L.M.</given-names></name></person-group><article-title>HMGA2 participates in transformation in human lung cancer</article-title><source>Mol. Cancer Res.</source><year>2008</year><volume>6</volume><fpage>743</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-07-0095</pub-id><pub-id pub-id-type="pmid">18505920</pub-id></element-citation></ref><ref id="B7-cancers-11-01482"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malek</surname><given-names>A.</given-names></name><name><surname>Bakhidze</surname><given-names>E.</given-names></name><name><surname>Noske</surname><given-names>A.</given-names></name><name><surname>Sers</surname><given-names>C.</given-names></name><name><surname>Aigner</surname><given-names>A.</given-names></name><name><surname>Schafer</surname><given-names>R.</given-names></name><name><surname>Tchernitsa</surname><given-names>O.</given-names></name></person-group><article-title>HMGA2 gene is a promising target for ovarian cancer silencing therapy</article-title><source>Int. J. Cancer</source><year>2008</year><volume>123</volume><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1002/ijc.23491</pub-id><pub-id pub-id-type="pmid">18452175</pub-id></element-citation></ref><ref id="B8-cancers-11-01482"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morishita</surname><given-names>A.</given-names></name><name><surname>Zaidi</surname><given-names>M.R.</given-names></name><name><surname>Mitoro</surname><given-names>A.</given-names></name><name><surname>Sankarasharma</surname><given-names>D.</given-names></name><name><surname>Szabolcs</surname><given-names>M.</given-names></name><name><surname>Okada</surname><given-names>Y.</given-names></name><name><surname>D&#x02019;Armiento</surname><given-names>J.</given-names></name><name><surname>Chada</surname><given-names>K.</given-names></name></person-group><article-title>HMGA2 is a driver of tumor metastasis</article-title><source>Cancer Res.</source><year>2013</year><volume>73</volume><fpage>4289</fpage><lpage>4299</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3848</pub-id><pub-id pub-id-type="pmid">23722545</pub-id></element-citation></ref><ref id="B9-cancers-11-01482"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Mu</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA</article-title><source>Clin. Cancer Res.</source><year>2014</year><volume>20</volume><fpage>1179</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1452</pub-id><pub-id pub-id-type="pmid">24423609</pub-id></element-citation></ref><ref id="B10-cancers-11-01482"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.T.</given-names></name><name><surname>Wu</surname><given-names>T.T.</given-names></name><name><surname>Lohse</surname><given-names>C.M.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>High-mobility group AT-hook 2: An independent marker of poor prognosis in intrahepatic cholangiocarcinoma</article-title><source>Hum. Pathol.</source><year>2014</year><volume>45</volume><fpage>2334</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2014.04.026</pub-id><pub-id pub-id-type="pmid">25245603</pub-id></element-citation></ref><ref id="B11-cancers-11-01482"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motoyama</surname><given-names>K.</given-names></name><name><surname>Inoue</surname><given-names>H.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Uetake</surname><given-names>H.</given-names></name><name><surname>Sugihara</surname><given-names>K.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name></person-group><article-title>Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>2334</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4667</pub-id><?supplied-pmid 18413822?><pub-id pub-id-type="pmid">18413822</pub-id></element-citation></ref><ref id="B12-cancers-11-01482"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>R.</given-names></name><name><surname>Kwon</surname><given-names>J.S.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis</article-title><source>Am. J. Cancer Res.</source><year>2016</year><volume>6</volume><fpage>249</fpage><lpage>259</lpage><?supplied-pmid 27186400?><pub-id pub-id-type="pmid">27186400</pub-id></element-citation></ref><ref id="B13-cancers-11-01482"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Mo</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Oncological role of HMGA2 (Review)</article-title><source>Int. J. Oncol.</source><year>2019</year><volume>55</volume><fpage>775</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.3892/ijo.2019.4856</pub-id><?supplied-pmid 31432151?><pub-id pub-id-type="pmid">31432151</pub-id></element-citation></ref><ref id="B14-cancers-11-01482"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinbach</surname><given-names>E.C.</given-names></name><name><surname>Garbus</surname><given-names>J.</given-names></name></person-group><article-title>Mechanism of action of reagents that uncouple oxidative phosphorylation</article-title><source>Nature</source><year>1969</year><volume>221</volume><fpage>1016</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1038/2211016a0</pub-id><pub-id pub-id-type="pmid">4180173</pub-id></element-citation></ref><ref id="B15-cancers-11-01482"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>P.K.</given-names></name><name><surname>Roberts</surname><given-names>M.J.</given-names></name><name><surname>Arend</surname><given-names>R.C.</given-names></name><name><surname>Samant</surname><given-names>R.S.</given-names></name><name><surname>Buchsbaum</surname><given-names>D.J.</given-names></name></person-group><article-title>Multi-targeted therapy of cancer by niclosamide: A new application for an old drug</article-title><source>Cancer Lett.</source><year>2014</year><volume>349</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2014.04.003</pub-id><?supplied-pmid 24732808?><pub-id pub-id-type="pmid">24732808</pub-id></element-citation></ref><ref id="B16-cancers-11-01482"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Mook</surname><given-names>R.A.</given-names><suffix>Jr.</suffix></name><name><surname>Premont</surname><given-names>R.T.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Niclosamide: Beyond an antihelminthic drug</article-title><source>Cell Signal.</source><year>2018</year><volume>41</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2017.04.001</pub-id><pub-id pub-id-type="pmid">28389414</pub-id></element-citation></ref><ref id="B17-cancers-11-01482"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osada</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>X.Y.</given-names></name><name><surname>Spasojevic</surname><given-names>I.</given-names></name><name><surname>Vandeusen</surname><given-names>J.B.</given-names></name><name><surname>Hsu</surname><given-names>D.</given-names></name><name><surname>Clary</surname><given-names>B.M.</given-names></name><name><surname>Clay</surname><given-names>T.M.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Morse</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>4172</fpage><lpage>4182</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3978</pub-id><pub-id pub-id-type="pmid">21531761</pub-id></element-citation></ref><ref id="B18-cancers-11-01482"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sack</surname><given-names>U.</given-names></name><name><surname>Walther</surname><given-names>W.</given-names></name><name><surname>Scudiero</surname><given-names>D.</given-names></name><name><surname>Selby</surname><given-names>M.</given-names></name><name><surname>Kobelt</surname><given-names>D.</given-names></name><name><surname>Lemm</surname><given-names>M.</given-names></name><name><surname>Fichtner</surname><given-names>I.</given-names></name><name><surname>Schlag</surname><given-names>P.M.</given-names></name><name><surname>Shoemaker</surname><given-names>R.H.</given-names></name><name><surname>Stein</surname><given-names>U.</given-names></name></person-group><article-title>Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer</article-title><source>J. Natl. Cancer Inst.</source><year>2011</year><volume>103</volume><fpage>1018</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr190</pub-id><pub-id pub-id-type="pmid">21685359</pub-id></element-citation></ref><ref id="B19-cancers-11-01482"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burock</surname><given-names>S.</given-names></name><name><surname>Daum</surname><given-names>S.</given-names></name><name><surname>Keilholz</surname><given-names>U.</given-names></name><name><surname>Neumann</surname><given-names>K.</given-names></name><name><surname>Walther</surname><given-names>W.</given-names></name><name><surname>Stein</surname><given-names>U.</given-names></name></person-group><article-title>Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: The NIKOLO trial</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><elocation-id>e297</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-018-4197-9</pub-id></element-citation></ref><ref id="B20-cancers-11-01482"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Tsueng</surname><given-names>G.</given-names></name><name><surname>Afrasiabi</surname><given-names>C.</given-names></name><name><surname>Su</surname><given-names>A.I.</given-names></name></person-group><article-title>BioGPS: Building your own mash-up of gene annotations and expression profiles</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>313</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1104</pub-id></element-citation></ref><ref id="B21-cancers-11-01482"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Macleod</surname><given-names>I.</given-names></name><name><surname>Su</surname><given-names>A.I.</given-names></name></person-group><article-title>BioGPS and MyGene.info: Organizing online, gene-centric information</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>561</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1114</pub-id><?supplied-pmid 23175613?><pub-id pub-id-type="pmid">23175613</pub-id></element-citation></ref><ref id="B22-cancers-11-01482"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Orozco</surname><given-names>C.</given-names></name><name><surname>Boyer</surname><given-names>J.</given-names></name><name><surname>Leglise</surname><given-names>M.</given-names></name><name><surname>Goodale</surname><given-names>J.</given-names></name><name><surname>Batalov</surname><given-names>S.</given-names></name><name><surname>Hodge</surname><given-names>C.L.</given-names></name><name><surname>Haase</surname><given-names>J.</given-names></name><name><surname>Janes</surname><given-names>J.</given-names></name><name><surname>Huss</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>BioGPS: An extensible and customizable portal for querying and organizing gene annotation resources</article-title><source>Genome Biol.</source><year>2009</year><volume>10</volume><fpage>e130</fpage><pub-id pub-id-type="doi">10.1186/gb-2009-10-11-r130</pub-id><?supplied-pmid 19919682?><pub-id pub-id-type="pmid">19919682</pub-id></element-citation></ref><ref id="B23-cancers-11-01482"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Kang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz430</pub-id><?supplied-pmid 31114875?><pub-id pub-id-type="pmid">31114875</pub-id></element-citation></ref><ref id="B24-cancers-11-01482"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Kang</surname><given-names>B.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id><?supplied-pmid 28407145?><pub-id pub-id-type="pmid">28407145</pub-id></element-citation></ref><ref id="B25-cancers-11-01482"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>A.I.</given-names></name><name><surname>Wiltshire</surname><given-names>T.</given-names></name><name><surname>Batalov</surname><given-names>S.</given-names></name><name><surname>Lapp</surname><given-names>H.</given-names></name><name><surname>Ching</surname><given-names>K.A.</given-names></name><name><surname>Block</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Soden</surname><given-names>R.</given-names></name><name><surname>Hayakawa</surname><given-names>M.</given-names></name><name><surname>Kreiman</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A gene atlas of the mouse and human protein-encoding transcriptomes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>6062</fpage><lpage>6067</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400782101</pub-id><pub-id pub-id-type="pmid">15075390</pub-id></element-citation></ref><ref id="B26-cancers-11-01482"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretina</surname><given-names>J.</given-names></name><name><surname>Caponigro</surname><given-names>G.</given-names></name><name><surname>Stransky</surname><given-names>N.</given-names></name><name><surname>Venkatesan</surname><given-names>K.</given-names></name><name><surname>Margolin</surname><given-names>A.A.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Wilson</surname><given-names>C.J.</given-names></name><name><surname>Lehar</surname><given-names>J.</given-names></name><name><surname>Kryukov</surname><given-names>G.V.</given-names></name><name><surname>Sonkin</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title><source>Nature</source><year>2012</year><volume>483</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature11003</pub-id><pub-id pub-id-type="pmid">22460905</pub-id></element-citation></ref><ref id="B27-cancers-11-01482"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>N.</given-names></name><name><surname>Guillen</surname><given-names>R.</given-names></name><name><surname>Chambers</surname><given-names>J.W.</given-names></name><name><surname>Leng</surname><given-names>F.</given-names></name></person-group><article-title>A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><fpage>e52</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv069</pub-id><pub-id pub-id-type="pmid">25653160</pub-id></element-citation></ref><ref id="B28-cancers-11-01482"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>T.</given-names></name><name><surname>Leng</surname><given-names>F.</given-names></name><name><surname>Wilson</surname><given-names>W.D.</given-names></name></person-group><article-title>Inhibition of high-mobility-group A2 protein binding to DNA by netropsin: A biosensor-surface plasmon resonance assay</article-title><source>Anal. Biochem.</source><year>2008</year><volume>374</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2007.10.023</pub-id><pub-id pub-id-type="pmid">18023407</pub-id></element-citation></ref><ref id="B29-cancers-11-01482"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname><given-names>V.K.</given-names></name><name><surname>Lindgren</surname><given-names>C.M.</given-names></name><name><surname>Eriksson</surname><given-names>K.F.</given-names></name><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Sihag</surname><given-names>S.</given-names></name><name><surname>Lehar</surname><given-names>J.</given-names></name><name><surname>Puigserver</surname><given-names>P.</given-names></name><name><surname>Carlsson</surname><given-names>E.</given-names></name><name><surname>Ridderstrale</surname><given-names>M.</given-names></name><name><surname>Laurila</surname><given-names>E.</given-names></name><etal/></person-group><article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nat. Genet.</source><year>2003</year><volume>34</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng1180</pub-id><pub-id pub-id-type="pmid">12808457</pub-id></element-citation></ref><ref id="B30-cancers-11-01482"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Tamayo</surname><given-names>P.</given-names></name><name><surname>Mootha</surname><given-names>V.K.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Ebert</surname><given-names>B.L.</given-names></name><name><surname>Gillette</surname><given-names>M.A.</given-names></name><name><surname>Paulovich</surname><given-names>A.</given-names></name><name><surname>Pomeroy</surname><given-names>S.L.</given-names></name><name><surname>Golub</surname><given-names>T.R.</given-names></name><name><surname>Lander</surname><given-names>E.S.</given-names></name><etal/></person-group><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="B31-cancers-11-01482"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A.</given-names></name><name><surname>Birger</surname><given-names>C.</given-names></name><name><surname>Thorvaldsdottir</surname><given-names>H.</given-names></name><name><surname>Ghandi</surname><given-names>M.</given-names></name><name><surname>Mesirov</surname><given-names>J.P.</given-names></name><name><surname>Tamayo</surname><given-names>P.</given-names></name></person-group><article-title>The molecular signatures database (MSigDB) hallmark gene set collection</article-title><source>Cell Syst.</source><year>2015</year><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><?supplied-pmid 26771021?><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="B32-cancers-11-01482"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlmann</surname><given-names>M.</given-names></name><name><surname>Kobelt</surname><given-names>D.</given-names></name><name><surname>Walther</surname><given-names>W.</given-names></name><name><surname>Mudduluru</surname><given-names>G.</given-names></name><name><surname>Stein</surname><given-names>U.</given-names></name></person-group><article-title>S100A4 in cancer metastasis: Wnt signaling-driven interventions for metastasis restriction</article-title><source>Cancers (Basel)</source><year>2016</year><volume>8</volume><elocation-id>e59</elocation-id><pub-id pub-id-type="doi">10.3390/cancers8060059</pub-id><?supplied-pmid 27331819?><pub-id pub-id-type="pmid">27331819</pub-id></element-citation></ref><ref id="B33-cancers-11-01482"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidle</surname><given-names>U.H.</given-names></name><name><surname>Birzele</surname><given-names>F.</given-names></name><name><surname>Kruger</surname><given-names>A.</given-names></name></person-group><article-title>Molecular targets and pathways involved in liver metastasis of colorectal cancer</article-title><source>Clin. Exp. Metastasis</source><year>2015</year><volume>32</volume><fpage>623</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1007/s10585-015-9732-3</pub-id><?supplied-pmid 26104118?><pub-id pub-id-type="pmid">26104118</pub-id></element-citation></ref><ref id="B34-cancers-11-01482"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname><given-names>F.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>S100A4 in cancer progression and metastasis: A systematic review</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>73219</fpage><lpage>73239</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18016</pub-id><pub-id pub-id-type="pmid">29069865</pub-id></element-citation></ref><ref id="B35-cancers-11-01482"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J.</given-names></name></person-group><article-title>The connectivity map: A new tool for biomedical research</article-title><source>Nat. Rev. Cancer</source><year>2007</year><volume>7</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nrc2044</pub-id><pub-id pub-id-type="pmid">17186018</pub-id></element-citation></ref><ref id="B36-cancers-11-01482"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J.</given-names></name><name><surname>Crawford</surname><given-names>E.D.</given-names></name><name><surname>Peck</surname><given-names>D.</given-names></name><name><surname>Modell</surname><given-names>J.W.</given-names></name><name><surname>Blat</surname><given-names>I.C.</given-names></name><name><surname>Wrobel</surname><given-names>M.J.</given-names></name><name><surname>Lerner</surname><given-names>J.</given-names></name><name><surname>Brunet</surname><given-names>J.P.</given-names></name><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Ross</surname><given-names>K.N.</given-names></name><etal/></person-group><article-title>The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1929</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1126/science.1132939</pub-id><pub-id pub-id-type="pmid">17008526</pub-id></element-citation></ref><ref id="B37-cancers-11-01482"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Narayan</surname><given-names>R.</given-names></name><name><surname>Corsello</surname><given-names>S.M.</given-names></name><name><surname>Peck</surname><given-names>D.D.</given-names></name><name><surname>Natoli</surname><given-names>T.E.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Gould</surname><given-names>J.</given-names></name><name><surname>Davis</surname><given-names>J.F.</given-names></name><name><surname>Tubelli</surname><given-names>A.A.</given-names></name><name><surname>Asiedu</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>1437</fpage><lpage>1452</lpage><comment>e1417</comment><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.049</pub-id><pub-id pub-id-type="pmid">29195078</pub-id></element-citation></ref><ref id="B38-cancers-11-01482"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Qi</surname><given-names>L.</given-names></name><name><surname>Knifley</surname><given-names>T.</given-names></name><name><surname>Piecoro</surname><given-names>D.W.</given-names></name><name><surname>Rychahou</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Mitov</surname><given-names>M.I.</given-names></name><name><surname>Martin</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>S100A4 alters metabolism and promotes invasion of lung cancer cells by up-regulating mitochondrial complex I protein NDUFS2</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>7516</fpage><lpage>7527</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.004365</pub-id><pub-id pub-id-type="pmid">30885944</pub-id></element-citation></ref><ref id="B39-cancers-11-01482"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>T.</given-names></name><name><surname>Wilhite</surname><given-names>S.E.</given-names></name><name><surname>Ledoux</surname><given-names>P.</given-names></name><name><surname>Evangelista</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>I.F.</given-names></name><name><surname>Tomashevsky</surname><given-names>M.</given-names></name><name><surname>Marshall</surname><given-names>K.A.</given-names></name><name><surname>Phillippy</surname><given-names>K.H.</given-names></name><name><surname>Sherman</surname><given-names>P.M.</given-names></name><name><surname>Holko</surname><given-names>M.</given-names></name><etal/></person-group><article-title>NCBI GEO: Archive for functional genomics data sets--update</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>991</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1193</pub-id></element-citation></ref><ref id="B40-cancers-11-01482"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigorian</surname><given-names>M.</given-names></name><name><surname>Tulchinsky</surname><given-names>E.</given-names></name><name><surname>Burrone</surname><given-names>O.</given-names></name><name><surname>Tarabykina</surname><given-names>S.</given-names></name><name><surname>Georgiev</surname><given-names>G.</given-names></name><name><surname>Lukanidin</surname><given-names>E.</given-names></name></person-group><article-title>Modulation of mts1 expression in mouse and human normal and tumor cells</article-title><source>Electrophoresis</source><year>1994</year><volume>15</volume><fpage>463</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1002/elps.1150150163</pub-id><pub-id pub-id-type="pmid">8055872</pub-id></element-citation></ref><ref id="B41-cancers-11-01482"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sack</surname><given-names>U.</given-names></name><name><surname>Walther</surname><given-names>W.</given-names></name><name><surname>Scudiero</surname><given-names>D.</given-names></name><name><surname>Selby</surname><given-names>M.</given-names></name><name><surname>Aumann</surname><given-names>J.</given-names></name><name><surname>Lemos</surname><given-names>C.</given-names></name><name><surname>Fichtner</surname><given-names>I.</given-names></name><name><surname>Schlag</surname><given-names>P.M.</given-names></name><name><surname>Shoemaker</surname><given-names>R.H.</given-names></name><name><surname>Stein</surname><given-names>U.</given-names></name></person-group><article-title>S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells</article-title><source>Mol. Biol. Cell</source><year>2011</year><volume>22</volume><fpage>3344</fpage><lpage>3354</lpage><pub-id pub-id-type="doi">10.1091/mbc.e10-09-0739</pub-id><?supplied-pmid 21795396?><pub-id pub-id-type="pmid">21795396</pub-id></element-citation></ref><ref id="B42-cancers-11-01482"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>U.</given-names></name><name><surname>Arlt</surname><given-names>F.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Sack</surname><given-names>U.</given-names></name><name><surname>Herrmann</surname><given-names>P.</given-names></name><name><surname>Walther</surname><given-names>W.</given-names></name><name><surname>Lemm</surname><given-names>M.</given-names></name><name><surname>Fichtner</surname><given-names>I.</given-names></name><name><surname>Shoemaker</surname><given-names>R.H.</given-names></name><name><surname>Schlag</surname><given-names>P.M.</given-names></name></person-group><article-title>Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis</article-title><source>Neoplasia</source><year>2011</year><volume>13</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1593/neo.101172</pub-id><?supplied-pmid 21403839?><pub-id pub-id-type="pmid">21403839</pub-id></element-citation></ref><ref id="B43-cancers-11-01482"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>S.C.</given-names></name><name><surname>Hodgson</surname><given-names>L.</given-names></name><name><surname>Rybin</surname><given-names>A.</given-names></name><name><surname>Toutchkine</surname><given-names>A.</given-names></name><name><surname>Hahn</surname><given-names>K.M.</given-names></name><name><surname>Lawrence</surname><given-names>D.S.</given-names></name><name><surname>Bresnick</surname><given-names>A.R.</given-names></name></person-group><article-title>A biosensor of S100A4 metastasis factor activation: Inhibitor screening and cellular activation dynamics</article-title><source>Biochemistry (Mosc.)</source><year>2008</year><volume>47</volume><fpage>986</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1021/bi7021624</pub-id><?supplied-pmid 18154362?><pub-id pub-id-type="pmid">18154362</pub-id></element-citation></ref><ref id="B44-cancers-11-01482"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malashkevich</surname><given-names>V.N.</given-names></name><name><surname>Dulyaninova</surname><given-names>N.G.</given-names></name><name><surname>Ramagopal</surname><given-names>U.A.</given-names></name><name><surname>Liriano</surname><given-names>M.A.</given-names></name><name><surname>Varney</surname><given-names>K.M.</given-names></name><name><surname>Knight</surname><given-names>D.</given-names></name><name><surname>Brenowitz</surname><given-names>M.</given-names></name><name><surname>Weber</surname><given-names>D.J.</given-names></name><name><surname>Almo</surname><given-names>S.C.</given-names></name><name><surname>Bresnick</surname><given-names>A.R.</given-names></name></person-group><article-title>Phenothiazines inhibit S100A4 function by inducing protein oligomerization</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>8605</fpage><lpage>8610</lpage><pub-id pub-id-type="doi">10.1073/pnas.0913660107</pub-id><?supplied-pmid 20421509?><pub-id pub-id-type="pmid">20421509</pub-id></element-citation></ref><ref id="B45-cancers-11-01482"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulyaninova</surname><given-names>N.G.</given-names></name><name><surname>Hite</surname><given-names>K.M.</given-names></name><name><surname>Zencheck</surname><given-names>W.D.</given-names></name><name><surname>Scudiero</surname><given-names>D.A.</given-names></name><name><surname>Almo</surname><given-names>S.C.</given-names></name><name><surname>Shoemaker</surname><given-names>R.H.</given-names></name><name><surname>Bresnick</surname><given-names>A.R.</given-names></name></person-group><article-title>Cysteine 81 is critical for the interaction of S100A4 and myosin-IIA</article-title><source>Biochemistry (Mosc.)</source><year>2011</year><volume>50</volume><fpage>7218</fpage><lpage>7227</lpage><pub-id pub-id-type="doi">10.1021/bi200853y</pub-id><?supplied-pmid 21749055?><pub-id pub-id-type="pmid">21749055</pub-id></element-citation></ref><ref id="B46-cancers-11-01482"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khamas</surname><given-names>A.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Shimokawa</surname><given-names>K.</given-names></name><name><surname>Mogushi</surname><given-names>K.</given-names></name><name><surname>Iida</surname><given-names>S.</given-names></name><name><surname>Ishiguro</surname><given-names>M.</given-names></name><name><surname>Mizushima</surname><given-names>H.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Uetake</surname><given-names>H.</given-names></name><name><surname>Sugihara</surname><given-names>K.</given-names></name></person-group><article-title>Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2&#x02019;-deoxycytidine, microarray and gene expression profile</article-title><source>Cancer Genom. Proteom.</source><year>2012</year><volume>9</volume><fpage>67</fpage><lpage>75</lpage></element-citation></ref><ref id="B47-cancers-11-01482"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadri</surname><given-names>H.</given-names></name><name><surname>Lambourne</surname><given-names>O.A.</given-names></name><name><surname>Mehellou</surname><given-names>Y.</given-names></name></person-group><article-title>Niclosamide, a Drug with many (Re)purposes</article-title><source>Chemmedchem</source><year>2018</year><volume>13</volume><fpage>1088</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201800100</pub-id><pub-id pub-id-type="pmid">29603892</pub-id></element-citation></ref><ref id="B48-cancers-11-01482"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Furumichi</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Morishima</surname><given-names>K.</given-names></name></person-group><article-title>KEGG: New perspectives on genomes, pathways, diseases and drugs</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id><pub-id pub-id-type="pmid">27899587</pub-id></element-citation></ref><ref id="B49-cancers-11-01482"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Goto</surname><given-names>S.</given-names></name></person-group><article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Res.</source><year>2000</year><volume>28</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="B50-cancers-11-01482"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Furumichi</surname><given-names>M.</given-names></name><name><surname>Morishima</surname><given-names>K.</given-names></name><name><surname>Tanabe</surname><given-names>M.</given-names></name></person-group><article-title>New approach for understanding genome variations in KEGG</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>590</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1093/nar/gky962</pub-id></element-citation></ref><ref id="B51-cancers-11-01482"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Duncan</surname><given-names>D.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>WEB-based gene set analysis toolkit (WebGestalt): Update 2013</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt439</pub-id><?supplied-pmid 23703215?><pub-id pub-id-type="pmid">23703215</pub-id></element-citation></ref><ref id="B52-cancers-11-01482"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Vasaikar</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Greer</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>WebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx356</pub-id><?supplied-pmid 28472511?><pub-id pub-id-type="pmid">28472511</pub-id></element-citation></ref><ref id="B53-cancers-11-01482"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Kirov</surname><given-names>S.</given-names></name><name><surname>Snoddy</surname><given-names>J.</given-names></name></person-group><article-title>WebGestalt: An integrated system for exploring gene sets in various biological contexts</article-title><source>Nucleic Acids Res.</source><year>2005</year><volume>33</volume><fpage>741</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1093/nar/gki475</pub-id><?supplied-pmid 15980575?><pub-id pub-id-type="pmid">15980575</pub-id></element-citation></ref><ref id="B54-cancers-11-01482"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mito</surname><given-names>J.K.</given-names></name><name><surname>Agoston</surname><given-names>A.T.</given-names></name><name><surname>Dal Cin</surname><given-names>P.</given-names></name><name><surname>Srivastava</surname><given-names>A.</given-names></name></person-group><article-title>Prevalence and significance of HMGA2 expression in oesophageal adenocarcinoma</article-title><source>Histopathology</source><year>2017</year><volume>71</volume><fpage>909</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1111/his.13310</pub-id><?supplied-pmid 28710822?><pub-id pub-id-type="pmid">28710822</pub-id></element-citation></ref><ref id="B55-cancers-11-01482"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name></person-group><article-title>High mobility group protein A2 overexpression indicates poor prognosis for cancer patients: A meta-analysis</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>1237</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23085</pub-id><pub-id pub-id-type="pmid">29416690</pub-id></element-citation></ref><ref id="B56-cancers-11-01482"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallante</surname><given-names>P.</given-names></name><name><surname>Sepe</surname><given-names>R.</given-names></name><name><surname>Puca</surname><given-names>F.</given-names></name><name><surname>Fusco</surname><given-names>A.</given-names></name></person-group><article-title>High mobility group a proteins as tumor markers</article-title><source>Front Med. (Lausanne)</source><year>2015</year><volume>2</volume><fpage>e15</fpage><pub-id pub-id-type="doi">10.3389/fmed.2015.00015</pub-id></element-citation></ref><ref id="B57-cancers-11-01482"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>A.</given-names><suffix>Jr.</suffix></name><name><surname>Da Costa</surname><given-names>N.M.</given-names></name><name><surname>Esposito</surname><given-names>F.</given-names></name><name><surname>De Martino</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>D.</given-names></name><name><surname>de Sousa</surname><given-names>V.P.</given-names></name><name><surname>Martins</surname><given-names>I.</given-names></name><name><surname>Nasciutti</surname><given-names>L.E.</given-names></name><name><surname>Fusco</surname><given-names>A.</given-names></name><name><surname>Ribeiro Pinto</surname><given-names>L.F.</given-names></name></person-group><article-title>HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>25872</fpage><lpage>25884</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8288</pub-id><pub-id pub-id-type="pmid">27027341</pub-id></element-citation></ref><ref id="B58-cancers-11-01482"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>A.Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Lai</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>H.H.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Loera</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers</article-title><source>Clin. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>2570</fpage><lpage>2580</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2542</pub-id><pub-id pub-id-type="pmid">21252160</pub-id></element-citation></ref><ref id="B59-cancers-11-01482"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Hao</surname><given-names>Y.</given-names></name></person-group><article-title>Clinicopathological and prognostic significance of HMGA2 overexpression in gastric cancer: A meta-analysis</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>100478</fpage><lpage>100489</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.19001</pub-id><pub-id pub-id-type="pmid">29245994</pub-id></element-citation></ref><ref id="B60-cancers-11-01482"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Fan</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name></person-group><article-title>Prognostic value of HMGA2 in human cancers: A meta-analysis based on literatures and TCGA datasets</article-title><source>Front Physiol.</source><year>2018</year><volume>9</volume><fpage>e776</fpage><pub-id pub-id-type="doi">10.3389/fphys.2018.00776</pub-id></element-citation></ref><ref id="B61-cancers-11-01482"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmailzadeh</surname><given-names>S.</given-names></name><name><surname>Mansoori</surname><given-names>B.</given-names></name><name><surname>Mohammadi</surname><given-names>A.</given-names></name><name><surname>Shanehbandi</surname><given-names>D.</given-names></name><name><surname>Baradaran</surname><given-names>B.</given-names></name></person-group><article-title>SiRNA-mediated silencing of HMGA2 induces apoptosis and cell cycle arrest in human colorectal carcinoma</article-title><source>J. Gastrointest. Cancer</source><year>2017</year><volume>48</volume><fpage>156</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1007/s12029-016-9871-z</pub-id><?supplied-pmid 27629422?><pub-id pub-id-type="pmid">27629422</pub-id></element-citation></ref><ref id="B62-cancers-11-01482"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>M.</given-names></name></person-group><article-title>HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>9963</fpage><lpage>9974</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24133</pub-id><?supplied-pmid 29515783?><pub-id pub-id-type="pmid">29515783</pub-id></element-citation></ref><ref id="B63-cancers-11-01482"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name></person-group><article-title>MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2</article-title><source>Biol. Open</source><year>2016</year><volume>5</volume><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1242/bio.015008</pub-id><?supplied-pmid 27095441?><pub-id pub-id-type="pmid">27095441</pub-id></element-citation></ref><ref id="B64-cancers-11-01482"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.Y.</given-names></name><name><surname>Tu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Ning</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name></person-group><article-title>MiR-4500 is epigenetically downregulated in colorectal cancer and functions as a novel tumor suppressor by regulating HMGA2</article-title><source>Cancer Biol. Ther.</source><year>2016</year><volume>17</volume><fpage>1149</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1080/15384047.2016.1235661</pub-id><pub-id pub-id-type="pmid">27686621</pub-id></element-citation></ref><ref id="B65-cancers-11-01482"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>C.Y.</given-names></name><name><surname>Yang</surname><given-names>P.M.</given-names></name><name><surname>Wu</surname><given-names>M.H.</given-names></name><name><surname>Huang</surname><given-names>C.C.</given-names></name><name><surname>Lee</surname><given-names>Y.C.</given-names></name><name><surname>Lee</surname><given-names>K.H.</given-names></name></person-group><article-title>Heat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells</article-title><source>PeerJ</source><year>2016</year><volume>4</volume><fpage>e1683</fpage><pub-id pub-id-type="doi">10.7717/peerj.1683</pub-id><pub-id pub-id-type="pmid">26893968</pub-id></element-citation></ref><ref id="B66-cancers-11-01482"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>W.</given-names></name><name><surname>To</surname><given-names>K.K.W.</given-names></name></person-group><article-title>Drug repurposing to overcome resistance to various therapies for colorectal cancer</article-title><source>Cell Mol. Life Sci.</source><year>2019</year><volume>76</volume><fpage>3383</fpage><lpage>3406</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03134-0</pub-id><pub-id pub-id-type="pmid">31087119</pub-id></element-citation></ref><ref id="B67-cancers-11-01482"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweizer</surname><given-names>M.T.</given-names></name><name><surname>Haugk</surname><given-names>K.</given-names></name><name><surname>McKiernan</surname><given-names>J.S.</given-names></name><name><surname>Gulati</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>H.H.</given-names></name><name><surname>Maes</surname><given-names>J.L.</given-names></name><name><surname>Dumpit</surname><given-names>R.F.</given-names></name><name><surname>Nelson</surname><given-names>P.S.</given-names></name><name><surname>Montgomery</surname><given-names>B.</given-names></name><name><surname>McCune</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0198389</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0198389</pub-id><pub-id pub-id-type="pmid">29856824</pub-id></element-citation></ref><ref id="B68-cancers-11-01482"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>D.B.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Page</surname><given-names>G.P.</given-names></name><name><surname>Sabripour</surname><given-names>M.</given-names></name></person-group><article-title>Microarray data analysis: From disarray to consolidation and consensus</article-title><source>Nat. Rev. Genet.</source><year>2006</year><volume>7</volume><fpage>55</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nrg1749</pub-id><pub-id pub-id-type="pmid">16369572</pub-id></element-citation></ref><ref id="B69-cancers-11-01482"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name></person-group><article-title>Designing microarray and RNA-Seq experiments for greater systems biology discovery in modern plant genomics</article-title><source>Mol. Plant</source><year>2015</year><volume>8</volume><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.molp.2014.11.012</pub-id><pub-id pub-id-type="pmid">25680773</pub-id></element-citation></ref><ref id="B70-cancers-11-01482"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schurch</surname><given-names>N.J.</given-names></name><name><surname>Schofield</surname><given-names>P.</given-names></name><name><surname>Gierlinski</surname><given-names>M.</given-names></name><name><surname>Cole</surname><given-names>C.</given-names></name><name><surname>Sherstnev</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>V.</given-names></name><name><surname>Wrobel</surname><given-names>N.</given-names></name><name><surname>Gharbi</surname><given-names>K.</given-names></name><name><surname>Simpson</surname><given-names>G.G.</given-names></name><name><surname>Owen-Hughes</surname><given-names>T.</given-names></name><etal/></person-group><article-title>How many biological replicates are needed in an RNA-seq experiment and which differential expression tool should you use?</article-title><source>RNA</source><year>2016</year><volume>22</volume><fpage>839</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1261/rna.053959.115</pub-id><pub-id pub-id-type="pmid">27022035</pub-id></element-citation></ref><ref id="B71-cancers-11-01482"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>K.D.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Irizarry</surname><given-names>R.A.</given-names></name><name><surname>Leek</surname><given-names>J.T.</given-names></name></person-group><article-title>Sequencing technology does not eliminate biological variability</article-title><source>Nat. Biotechnol.</source><year>2011</year><volume>29</volume><fpage>572</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1038/nbt.1910</pub-id><?supplied-pmid 21747377?><pub-id pub-id-type="pmid">21747377</pub-id></element-citation></ref><ref id="B72-cancers-11-01482"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>M.E.</given-names></name><name><surname>Phipson</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Law</surname><given-names>C.W.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Smyth</surname><given-names>G.K.</given-names></name></person-group><article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><fpage>e47</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><?supplied-pmid 25605792?><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="B73-cancers-11-01482"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y.</given-names></name><name><surname>Hochberg</surname><given-names>Y.</given-names></name></person-group><article-title>Controlling the false discovery rate: A Practical and Powerful Approach to Multiple Testing</article-title><source>J. R. Stat. Soc. Series B (Methodol.)</source><year>1995</year><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="B74-cancers-11-01482"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>DEGseq: an R package for identifying differentially expressed genes from RNA-seq data</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>136</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp612</pub-id><?supplied-pmid 19855105?><pub-id pub-id-type="pmid">19855105</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-11-01482-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Gene expression profiles of high mobility group adenine&#x02013;thymine (AT)-hook 2 (HMGA2) in normal and cancerous tissues/cells. (<bold>A</bold>) Gene expression profiles of HMGA2 were analyzed using the BioGPS database. Two datasets, GeneAtlas U133A, gcrma and The Cancer Cell Line Encyclopedia (CCLE) (the embedded graph), were used for analysis; (<bold>B</bold>) pan-cancer gene expression profiles of HMGA2 were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. Significant HMGA2 overexpression in cancers are highlighted in red.</p></caption><graphic xlink:href="cancers-11-01482-g001"/></fig><fig id="cancers-11-01482-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The prognostic impact of HMGA2 on overall and disease-free survival of cancer patients. The Kaplan&#x02013;Meier survival plots for cancer patients with high and low HMGA2 expression were generated using the GEPIA database. TPM, transcript per million.</p></caption><graphic xlink:href="cancers-11-01482-g002"/></fig><fig id="cancers-11-01482-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Characterization of HMGA2-overexpressing colorectal cancer cells. (<bold>A</bold>) The mRNA and protein expressions of HMGA2 in DLD-1-Vector and DLD-1-HMGA2 cells were analyzed by qPCR and Western blotting, respectively; (<bold>B</bold>) the growth rate of DLD-1-Vector and DLD-1-HMGA2 cells was measured by cell counts at 1&#x02013;4 days; (<bold>C</bold>) the growth rate of DLD-1-Vector and DLD-1-HMGA2 cells on mice was measured using xenograft; (<bold>D</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of netropsin for 72 h. The cell viability was analyzed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay; (<bold>E</bold>) the protein expression of HMGA2 in DLD-1-Vector, DLD-1-HMGA2, and HCT116 cells was analyzed by Western blot analysis; (<bold>F</bold>) DLD-1 and HCT116 cells were treated with various doses of netropsin for 72 h. The cell viability was analyzed by an MTT assay.</p></caption><graphic xlink:href="cancers-11-01482-g003"/></fig><fig id="cancers-11-01482-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Upregulation of S100 calcium-binding protein A4 (S100A4) in HMGA2-overexpression colorectal cancer cells. (<bold>A</bold>) The differentially expressed genes (DEGs) in DLD-1-HMGA2 cells were analyzed by Gene Set Enrichment Analysis (GSEA) for hallmark enrichment; (<bold>B</bold>) a Venn diagram for the overlapped genes among epithelial&#x02013;mesenchymal transition (EMT) and angiogenesis hallmarks, and top 10 up- and down-regulated DEGs in DLD-1-HMGA2 cells; (<bold>C</bold>) the mRNA and protein expressions of S100A4 in DLD-1-Vector and DLD-1-HMGA2 cells were analyzed by qPCR and Western blotting (WB), respectively. The level of S100A4 protein in the 24-h culture medium from DLD-1-Vector and DLD-1-HMGA2 cells was detected by enzyme-linked immunosorbent assay (ELISA); (<bold>D</bold>) the Kaplan&#x02013;Meier survival plots for colorectal cancer patients with high and low S100A4 expression were generated using the GEPIA database. TPM, transcript per million.</p></caption><graphic xlink:href="cancers-11-01482-g004"/></fig><fig id="cancers-11-01482-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Connectivity mapping for the gene signature in DLD-1-HMGA2 cells. (<bold>A</bold>) Connections of HMGA2-driven gene signature with the gene knockdown/overexpression were analyzed by querying the CLUE database. Connections were viewed as a heat map ranked by the summary connectivity score; (<bold>B</bold>) connections of HMGA2-driven gene signature with the S100A4-inhibitory small molecules were analyzed by querying the CLUE database. Connections were viewed as a heat map with each connectivity score in individual cell line. KD, knockdown. OE, overexpression.</p></caption><graphic xlink:href="cancers-11-01482-g005"/></fig><fig id="cancers-11-01482-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>The clinical implication of S100 calcium-binding protein A4 (S100A4)-targeting niclosamide for colorectal cancer. The upper part: The most similar and dissimilar genes with HMGA2 were generated using GSEA and were visualized as a heat map. The lower part: Connections of HMGA2-driven gene signature in colorectal cancer patients with the HMGA2/S100A4 knockdown and niclosamide were analyzed by querying the CLUE database (<uri xlink:href="https://clue.io/">https://clue.io/</uri>). Connections were viewed as a heat map ranked by the summary connectivity score.</p></caption><graphic xlink:href="cancers-11-01482-g006"/></fig><fig id="cancers-11-01482-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Effect of niclosamide on S100A4 expression and cancer growth in HMGA2-overexpressing colorectal cancer cells. (<bold>A</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of niclosamide for 48 h (the upper part), or 1 &#x003bc;M niclosamide for 1&#x02013;3 days (the lower part). Whole cell lysates were prepared and subjected to Western blot analysis; (<bold>B</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of niclosamide for 72 h. The cell viability was analyzed by an MTT assay; (<bold>C</bold>) the protein expression of HMGA2 and S100A4 in DLD-1 and HCT116 cells was analyzed by Western blot analysis; (<bold>D</bold>) DLD-1 and HCT116 cells were treated with various doses of niclosamide for 72 h. The cell viability was analyzed by an MTT assay; (<bold>E</bold>) DLD-1-Vector (1 &#x000d7; 10<sup>6</sup>) and DLD-1-HMGA2 (1 &#x000d7; 10<sup>5</sup>) cells were subcutaneously injected into the right and left flank of nude mice. Then, mice received vehicle [5% DMSO in phosphate-buffered saline (PBS); n = 5] or niclosamide (20 mg/kg; n = 5) for four weeks. Tumor volumes were measured twice per week.</p></caption><graphic xlink:href="cancers-11-01482-g007"/></fig><fig id="cancers-11-01482-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Effect of S100A4 inhibition on cell viability in HMGA2-overexpressing colorectal cancer cells. (<bold>A</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of sulindac for 48 h. Whole cell lysates were prepared and subjected to Western blot analysis; (<bold>B</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of sulindac for 72 h. The cell viability was analyzed by an MTT assay; (<bold>C</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of cardamonin for 48 h. Whole cell lysates were prepared and subjected to Western blot analysis; (<bold>D</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of cardamonin for 72 h. The cell viability was analyzed by an MTT assay; (<bold>E</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were transfected with S100A4 siRNA for 48 h, and then treated with 1 &#x003bc;M niclosamide for 72 h. The cell viability was analyzed by an MTT assay; (<bold>F</bold>) DLD-1-Vector and DLD-1-HMGA2 cells were transfected with S100A4 siRNA for 48 h, and then colony formation assay was performed.</p></caption><graphic xlink:href="cancers-11-01482-g008"/></fig><fig id="cancers-11-01482-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Pathway enrichment for niclosamide-treated cells. (<bold>A</bold>) A Venn diagram showed the numbers of overlapped genes in niclosamide-treated DLD-1-Vector and DLD-1-HMGA2 cells; (<bold>B</bold>) the pathway enrichment results for the downregulated genes in niclosamide-treated DLD-1-HGMA2 cells; (<bold>C</bold>) the mapping of cell cycle pathway for the upregulated (red) and downregulated (blue) genes in niclosamide-treated DLD-1-HGMA2 cells.</p></caption><graphic xlink:href="cancers-11-01482-g009"/></fig><table-wrap id="cancers-11-01482-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-11-01482-t001_Table 1</object-id><label>Table 1</label><caption><p>Top 10 up- and down-regulated genes in high mobility group adenine&#x02013;thymine (AT)-hook 2 (HMGA2)-overexpressing DLD-1 cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Symbol</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fold Change (Log<sub>2</sub>)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>CASQ1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">calsequestrin 1 (fast-twitch, skeletal muscle)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.20</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>QPRT</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">quinolinate phosphoribosyltransferase</td><td align="center" valign="middle" rowspan="1" colspan="1">4.14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S100A4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">S100 calcium binding protein A4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.33</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>MYLK</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">myosin light chain kinase</td><td align="center" valign="middle" rowspan="1" colspan="1">3.21</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>BDNF</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">brain-derived neurotrophic factor</td><td align="center" valign="middle" rowspan="1" colspan="1">3.08</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>PRKCQ</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">protein kinase C, theta</td><td align="center" valign="middle" rowspan="1" colspan="1">2.86</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>PCOLCE2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"> procollagen C-endopeptidase enhancer 2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.77</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>PDE2A</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">phosphodiesterase 2A</td><td align="center" valign="middle" rowspan="1" colspan="1">2.70</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>LCN2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">lipocalin 2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.45</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>PIK3AP1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">integrin, alpha 1</td><td align="center" valign="middle" rowspan="1" colspan="1">2.32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>ZNF711</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">zinc finger protein 711</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.26</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>PBDC1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">polysaccharide biosynthesis domain containing 1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.72</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>NPNT</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">nephronectin</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.57</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>CFTR</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.07</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>NPTX2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">neuronal pentraxin II</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>KIT</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.99</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>SH3BGRL</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">SH3 domain binding glutamic acid-rich protein like</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.90</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>METTL7A</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">methyltransferase like 7A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.70</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>CBWD1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">COBW domain containing 1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.62</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>CDC27</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cell division cycle 27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.57</td></tr></tbody></table></table-wrap><table-wrap id="cancers-11-01482-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-11-01482-t002_Table 2</object-id><label>Table 2</label><caption><p>The Gene Set Enrichment Analysis (GSEA) for hallmarks enriched in HMGA2-overexpressing DLD-1 cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Hallmark <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Genes in Pathway</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Pathway Genes Differentially Expressed (% of total)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">NES <sup>2</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDR <sup>3</sup> (<italic>q</italic> Value)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epithelial&#x02013;mesenchymal transition</td><td align="center" valign="middle" rowspan="1" colspan="1">197</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.483</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.166</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Myogenesis</td><td align="center" valign="middle" rowspan="1" colspan="1">198</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (21%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.419</td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td><td align="center" valign="middle" rowspan="1" colspan="1">0.151</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiogenesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (22%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.373</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.083</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.154</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Hallmarks with false discovery rate (FDR) &#x0003c; 0.25 were shown. <sup>2</sup> Normalized enrichment score. <sup>3</sup> False discovery rate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="cancers-11-01482-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-11-01482-t003_Table 3</object-id><label>Table 3</label><caption><p>The candidate genes upregulated in HMGA2-overexpressing DLD-1 cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subcellular Localization</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Ontology (Biological Process) <sup>1</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>MYLK</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">myosin light chain kinase</td><td align="center" valign="middle" rowspan="1" colspan="1">stress fiber</td><td align="center" valign="middle" rowspan="1" colspan="1">positive regulation of cell migration, muscle contraction</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>BDNF</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">brain-derived neurotrophic factor</td><td align="center" valign="middle" rowspan="1" colspan="1">extracellular</td><td align="center" valign="middle" rowspan="1" colspan="1">negative regulation of apoptotic process</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>PCOLCE2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">procollagen C-endopeptidase enhancer 2</td><td align="center" valign="middle" rowspan="1" colspan="1">extracellular</td><td align="center" valign="middle" rowspan="1" colspan="1">positive regulation of peptidase activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S100A4</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S100 calcium binding protein A4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">extracellular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">epithelial to mesenchymal transition, positive regulation of I-kappaB kinase/NF-kappaB signaling</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Gene information was obtained from the National Center for Biotechnology Information (NCBI) gene database (<uri xlink:href="https://www.ncbi.nlm.nih.gov/gene">https://www.ncbi.nlm.nih.gov/gene</uri>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="cancers-11-01482-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-11-01482-t004_Table 4</object-id><label>Table 4</label><caption><p>A list of reported S100 calcium-binding protein A4 (S100A4) inhibitors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism for S100A4 Inhibition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose for S100A4 Inhibition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose in CMap</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Niclosamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">anthelminthic agent</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">inhibition of the Wnt/&#x003b2;-catenin pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 nM~10 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-cancers-11-01482" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcimycin (A23187)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">calcium ionophore</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.D. <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-cancers-11-01482" ref-type="bibr">40</xref>,<xref rid="B41-cancers-11-01482" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sulindac</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nonsteroidal anti-inflammatory drug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 nM~10 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-cancers-11-01482" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trifluoperazine</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">phenothiazines</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">disruption of the S100A4/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">50~100 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 nM~10 &#x003bc;M</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B43-cancers-11-01482" ref-type="bibr">43</xref>,<xref rid="B44-cancers-11-01482" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prochlorperazine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Perphenazine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlorprothixene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flupentixol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluphenazine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 nM~10 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSC-95397</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDC25 inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.D.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-cancers-11-01482" ref-type="bibr">45</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> N.D. means not determined.</p></fn></table-wrap-foot></table-wrap></floats-group></article>